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During the three years of her PhD, Kristel Martinelli focused her research 
project on design, instrumental development and application of a novel, flow-
assisted technology for the separation and selection of cells, in particular stem 
cells. The importance of this technology concerns the particularly gentle method 
by which cells are swept down the separation device and are, then separated. 
This allows full maintenance of the physiological characteristic of the cells, a 
key point to make cells, and more specifically stem cells, able to be used for 
further biological characterization or cell culture. The novel technology 
implements a cluster of patents of the University of Bologna (IT1371772, US 
8263359, CA2649234) into an instrumentation that will be addressed to the 
market. The physical principle underpinning this novel technology is that Earth’s 
gravity assists the dynamic fractionation of cells suspended in a liquid stream 
based on differences in physical-morphological properties (size, shape, density, 
surface features) of the cells. This turns out into a unique tool for non-invasive 
cell sorting. "Non-invasive" means that cells can be separated at a highly pure 
level (>90%) just by physical means. This avoids the use of surface immune-
markers that can modify cell biology and promote the unpredicted outcome of 
their molecular characterization.  
The candidate focused on the analytical, instrumental aspects of the technology 
using, first, cell samples, either from cell cultures or from real, raw samples. 
Using cells of different nature, particular emphasis was given to the application 
to mesenchymal stem cells and on the relevant search of biocompatibility and 
 adequacy of the technical solutions chosen for developing the instrumental 
prototypes into a possible, future product.  
Indeed the candidate acquired good experience also in validation and 
development of flow-assisted separation methods, analytical instrumentation 
design and development, techniques for cell characterization like flow cytometry 
and related FACS, magnetic-assisted cell sorting (MACS), 
immunofluorescence, microscopy, cell culturing and cloning. The possible 
orientation to a market outcome of the PhD project made the candidate getting 
acquainted also on strategic marketing, communication techniques and 
business planning.  
During the PhD project, the candidate attended national and international 
congresses and events, also presenting poster and oral communications, 
among which, in 2016, a presentation to MEDTEC Europe, Stuttgart (Germany), 
to the “International Summer School - Innovation and Technology Management 
in Medical and Pharmaceutical Biotechnology”, of the Bologna Business 
School, and to the “Y-RICH-Young Research Ideas”, Università di Roma “La 
Sapienza”. With an entrepreneurship project based on the technology 
developed during her PhD, the candidate got the final of the “Premio Marzotto 
2014”, the Italian, most important competition for startup projects.  
The candidate has developed understanding of all the issues involved. She 
acquired a good mastery of the experimental techniques, demonstrated skills of 
organization, coordinated well with laboratory colleagues, and showed ability to 
relate with external collaborators. She also developed “soft skills” that will make 
her able to be competitive on business-related activities.  
In my opinion Kristel Martinelli has carried out a very good work for the thesis.  
The Board expresses a very good score on the activity carried out by the 
candidate during the whole cycle of doctorate and considers her worthy to attain 
the PhD in Chemistry. 
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 Aim of the study and Introduction 
 
My PhD research project was focused on the development of a brand new 
instrumentation for the separation of particles, chiefly of interest for medical and 
clinical issues, thanks to the advantage related to the preservation of the 
sample or “minimum manipulation” in the medical field. The competitive 
advantage, respect to the state of art of current cell separation techniques, is 
the unique and specific separation method based solely on the morpho-physical 
proprieties of particles moving inside the flow of a capillary separation channel. 
The combination of forces developed inside the channel and due to the flow 
composed of a biocompatible liquid and the Earth Gravitation Field, joined to 
the geometries of the system and the sample manipulation procedures, allows 
the separation in time and in space of particles with different physical 
proprieties. The different population can be collected, characterized and reused 
for further applications. This feature is particularly relevant when the 
preservation of the native proprieties of the sample is unavoidable and when the 
traditional parameters of traditional techniques are not effective or not efficient 
for the separation of the species contained in a suspension. This is a significant 
limit when we’re talking about drugs or therapies presenting peculiar 
characteristics, as the stromal cell population and in particular the mesenchymal 
stem cells (MSCs), where the complexity of the sample in reason of their “not 
specialized” state, leads to a really heterogeneous population, preventing the 
identification by traditional protocols. This heterogeneity can be tapped by the 
novel instrumentation, first of all in the regenerative medicine field that uses cell 
based therapy, most of them belonging from stem cell or derived or progenitors 
cells, samples not to be compromised during the analysis or the separation 
procedures. MSCs are the most promising stem cell type for cell-based 
therapies since they are virtually present in all adult tissues and possess tissue 
regenerative and immunosuppressive properties. MSCs are adult stem cells 
which can be induced to enter various mesenchymal lineage pathways to 
differentiate towards the more specialized osteogenic, chondrogenic, myogenic 
and adipogenic cell lineages. They appear to be particularly suitable for clinical 
 applications in the fields of cell therapy and tissue reconstruction, for treatments 
of compromises organs and tissues. Mesenchymal cells are located in all 
human tissues, but some tissues are particularly rich in MSCs such as the fatty 
tissue, spinal cord (bone marrow), dental pulp and neonatal tissues. Starting 
from these sources I studied the behavior of stem cells before, during and after 
the separation procedure to build up the technology respect the biological 
requirements of manipulation and optimizing the methods respect the 
proprieties of stemness of the different fractions resulting from the separation.  
Moving from this request, I developed a technology that builds on the patented 
method (IT1371772, US 8263359, CA2649234) for gentle stem cell separation 
and evolves into an instrumentation serviceable and scalable to be brought on 
the market and available for “stringent criteria of manipulation” applications.  
To meet the demands of the market, I considered the whole project in order to 
insure an organic and coordinated development of the product with the aim to 
guarantee a fully functional product, thought to be appropriate for the beta-
testing and the first placement on the market. Briefly, the project of my research 
was to transform a method of separation compliant for cell samples into a full 
automated product usable by not specialized personnel, related with a full 
protocol of separation portfolio which include a panel of characterization off-&-
on-line cell population and subpopulation, ensuring the compliance of the whole 
process with Class IIb Medical Device certification. This latter aspect worked as 
the “shadow guideline” moving with the project progress, starting from the 
suppliers, materials and manufacturing techniques/ procedures, transports, 
destination of use and environment, and finishing with the biologic cell sample 
selection and timing, cell characterizations, sterilization and operational 
methods dependent on methodical daily working rules of the target client. 
Coordinating all these aspects allowed to gain a first instrumentation boasting 
the principal features for future medical applications or immediate “low scale” 
amount of cells in particular therapies.   
The resulting product developed in compliance with engineering and 
biotechnological requirements, merged with industrial and production and 
 strategies, in order to helpfully supply the Regenerative Medicine sector, is 
called Celector®. 
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Chapter 1 
Stem cells and Regenerative 
Medicine 
 
 
Stem Cells: Basics 
 
Stem cells are a population of precursor cells that are capable of developing into 
many different cell types in the body. When a stem cell divides, each new cell has 
the potential either to remain a stem cell or differentiate into another type of cell 
with a more specialized function. Stem cells are distinguished from other cell types 
in the body by capability of self- renewal and under certain conditions induced to 
differentiate into specific cells. In some organs, (for example the bone marrow, or 
skin), stem cells regularly divide to repair and replace worn out tissues which was 
discovered in the early 1960s, and knowledge about their characteristics and 
composition has come a long way. The existence of stem cells was first 
demonstrated in 1960 by Till and McCulloch in a study on hematopoiesis. The 
establishment of the concept of hematopoietic stem cells (HSCs) was followed by 
the discovery of tissue stem cells in other organs in mammals, for example, 
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epithelial stem cells, neural stem cells, and intestinal stem cells1. Stem cells are 
important for living organisms for many reasons. In the 3 to 5 day old embryo, 
called a blastocyst, the inner cells give rise to the entire body of the organism, 
including all of the many specialized cell types and organs such as the heart, lung, 
skin, sperm, eggs and other tissues. In some adult tissues, such as bone marrow, 
muscle, and brain, discrete populations of adult stem cells generate replacements 
for cells that are lost through normal wear and tear, injury, or disease  
Stem cells differ from other kinds of cells in the body. All stem cells regardless of 
their source have three general properties: Stem cells are unspecialized. One of 
the fundamental properties of a stem cell is that it does not have any tissue-specific 
structures and cannot work with its neighbors to pump blood through the body (like 
a heart muscle cell); it cannot carry molecules of oxygen through the bloodstream 
(like a red blood cell); and it cannot fire electrochemical signals to other cells that 
allow the body to move or speak (like a nerve cell). 
However, unspecialized stem cells can give rise to specialized cells, including 
heart muscle cells, blood cells, or nerve cells. Stem cells are capable of dividing 
and renewing themselves for long periods. When cells replicate themselves many 
times over it is called proliferation. A starting population of stem cells that 
proliferates for many months in the laboratory can yield millions of cells. If the 
resulting cells continue to be unspecialized, like the parent stem cells, the cells are 
said to be capable of long-term self-renewal. Stem cells can give rise to specialized 
cells. When unspecialized stem cells give rise to specialized cells, the process is 
called differentiation. Scientists are just beginning to understand the signals inside 
and outside cells that trigger stem cell differentiation. The internal signals are 
controlled by a cell's genes, which are interspersed across long strands of DNA, 
                                                          
1
 Fuchs and Segre, 2000 
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and carry coded instructions for all the structures and functions of a cell. The 
external signals for cell differentiation include chemicals secreted by other cells, 
physical contact with neighboring cells, and certain molecules in the 
microenvironment. A number of experiments have reported that certain adult stem 
cell types can differentiate into cell types seen in organs or tissues other than those 
expected from the cells' predicted lineage (that is, brain stem cells that differentiate 
into blood cells or blood forming cells that differentiate into cardiac muscle cells 
and so forth). This reported phenomenon is called transdifferentiation. 
 
Types of stem cells 
Stem cells can be divided based on their self-renewal and potency2. Self-renewal 
is the ability to go through numerous cycles of cell division while maintaining the 
undifferentiated state while potency is the capacity to differentiate into specialized 
cell types. Based on the potency, stem cells can be divided into five groups. The 
first type is the totipotent stem cells. These cells can differentiate into embryonic 
and extraembryonic cell types. These cells are produced by fusion of an egg and 
sperm cell. The second type is pluripotent stem cells. These cells are the 
progenies of totipotent cells and can differentiate into almost all cells except 
extraembryonic cell types. The cell has the potential to differentiate to any of the 
three germ layers are examples of this type. The third type is the multipotent stem 
cells which can differentiate into a number of cells, but only those of a closely 
related family of cells. The fourth type is the oligopotent stem cells. These cells can 
differentiate into only a few cells, such as lymphoid or myeloid stem cells. Finally, 
the fifth group is the unipotent cells. Therefore, all types of stem cells have the 
ability of self-renewal but their potency is different and depends on the source that 
                                                          
2 Zhang and Cheng, 2013 
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they have arisen from3. Based on their source, stem cell can also be classified as 
embryonic, fetal, adult, amniotic cord blood and Induced pluripotent. 
 
Stem cell bioprocessing4 
The success of stem cell bioprocessing relies on robust and reproducible culture 
conditions and processes. For stem cell bioprocessing, this includes the scale-up 
of stem cells to a differentiated end product of sufficient quality and quantity for 
clinical and commercial goals. Automation and the use of an efficient bioprocess 
paradigm are imperative for the creation of successful clinical products. The design 
principles 5pertinent to stem cell bioprocessing can be categorized into three 
groups: process components; process requirements and process function, as 
summarized in Figure 1. A combination of generic, ‘off-the-shelf’ and personalized 
manufacturing paradigms must be considered as no single technology satisfies all 
requirements6 (Figure 1.1) 
 
                                                          
3 Yao et al., 2012 
4 Dubie et al. Journal of Cell Biology and Genetics, Vol. 4(4), pp. 40-52,,2014 
5 Lim et al., 2007 
6  Mark et al., 2009 
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Figure 1.1 Design principles for stem cell bioprocesses. Source: (Lim et al., 2007). 
 
MSC in Regenerative Therapy 
The regenerative potential of MSC isolated from different tissues has been shown  
to undergo alteration according to the tissue of isolation78. It has been shown that 
BM-MSC possess a higher potential in giving rise to osteoblasts and 
chondrocytes9, whereas adipose tissue-derived MSC (AT-MSC) have been shown 
to contribute more successfully  to capillary-like network formation in vitro as well 
as vasculogenesis in vivo [85, 86]. Umbilical cord blood- (UCB-) MSC also showed 
a high potency in giving rise to pericytes during vasculogenesis, whereas their 
potential for osteogenic differentiation has been shown to diminish compared to 
                                                          
7 A. Reinisch, N. A. Hofmann, A. C. Obenauf et al., Blood, vol. 113, no. 26, pp. 6716–6725, 2009 
 
8 N. A. Hofmann, A. Ortner, R. O. Jacamo et al., PLoS ONE, vol. 7, no. 9, Article ID e44468, 2012. 
9 International Journal of Molecular Sciences, vol. 14, no. 9, pp.17986–18001, 2013 
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BM-MSC 10, which still play as the gold standard for osteogenic differentiation and 
regeneration. AMN-MSC were also shown to successfully participate in 
neurogenesis, whereas such a regenerative potential has not been distinguished in 
UC-MSC11. Amniotic membrane-derived MSC, however, have not been shown to 
participate in the process of  vasculogenesis as successfully as UC-, UCB-, AT-, 
and BM-MSC did [86]. Despite the fact that DPSC and BM-MSC are regulated by 
similar factors and they also possess a similar protein expression profile, these 
populations have been shown to alter significantly in their proliferative capacity in 
vitro and, more importantly, in their regenerative capacity in vivo12. BM-MSC give 
rise to bone tissue in the mouse model under treatment as described in studies. 
The chondrogenic and adipogenic potential of BM-MSC has been higher compared 
to that of DPSC13. Conversely, the neurogenic differentiation potential of dental 
mesenchymal stem cells might be more robust compared to that of BMMSC, since 
these cells possess neural crest origin. BM-, dental pulp- (DP-), and adipose 
tissue-  (AT-) derivedMSC have revealed a greater promise in regenerative therapy 
since these adult stem cells might promote patientspecific regenerative 
interventions. MSC are attractive alternatives for regeneration of the injured and/or 
deficient cells and tissues due to their multipotent differentiation capacity as well as 
their immunomodulatory and anti-inflammatory properties through cellular crosstalk 
and production of bioactive molecules. MSC have the unique potential either to 
directly participate in regeneration and repair processes or to play an immune 
                                                          
10 A. Ardeshirylajimi, M. Mossahebi-Mohammadi, S. Vakilian et al., Cell Proliferation, vol. 48, no.1, 
pp. 47–58, 2015. 
 
11  E. Y. Kim, K.-B. Lee, and M. K. Kim, BMB Reports, vol. 47, no. 3, pp. 135–140, 2014. 
 
12 S. Shi, P. G. Robey, and S. Gronthos,, Bone, vol. 29, no. 6, pp. 532–539, 2001. 
13 W. Zhang, X. F.Walboomers, S. Shi, M. Fan, and J. A. Jansen, Tissue Engineering, vol. 12, no. 
10, pp. 2813–2823, 2006. 
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modulatory role to enhance treatment of autoimmune diseases such as type 1 
diabetes (T1D). 
Focus on the most interesting source of 
mesenchymal stem cells: adipose tissue 
derived MSCs 
 
In the last decade, rapid evolution in the biology and biotechnology’s fields led to 
development of different viable cell-based medical applications, which hold a high 
potential in treatment of several diseases still lacking a specific therapy. In this 
context, stem cells are the most promising source of cells, mainly because of their 
limitless avalaibility and easy manipulation (Guilak et al, 2010). 
 
Stem cells can be defined as cells with the capability of generating daughter cells 
(self-renewal property) and having multi-lineage differentiation capacity 
(EMA/CAT/571134/2009). Stem cells are able to proliferate in an undifferentiated 
form and include: 
 embryonic stem cells derived from blastocysts (hESC);  
 adult and/or somatic stem cell, including:  
 haematopoietic stem cells (HSCs);  
 mesenchymal stromal/stem cells (MSCs);  
 tissue-specific progenitor cells, unipotent cells that can develop into a limited 
panel of tissues;  
 induced pluripotent stem cells (iPSs).  
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Among all these types of stem cells, MSCs are the most promising for cell-based 
therapies since they are virtually present in all adult tissues (14) and possess tissue 
regenerative (Pittenger et al., 1999) and immunosuppressive properties (Aggarwal 
et al., 2005). 
 
MSCs are adult stem cells which can be induced to enter various mesenchymal 
lineage pathways to differentiate towards the more specialized osteogenic, 
chondrogenic, myogenic and adipogenic cell lineages. Although bone marrow has 
been considered for years the classical reservoir of MSCs (BM-MSCs), several 
new sources are currently under investigation. In particular, the adipose tissue has 
been proven to be an increasingly attractive source of MSCs for mesenchymal 
tissues regeneration15, since fat is easily obtainable in large quantities and it yields 
a cells number per gram of tissue which is 500-fold higher than the bone marrow.16 
 
MSCs isolated from different tissues differently reacts to inductive molecules, thus 
reflecting the characteristics of tissues of origin (Caplan, 2008); however, in 
culture, BM-MSCs and adipose-derived MSCs (ASCs) share an important 
combination of features: 
1) adherence to plastic 1718 
2) morphology19;  
                                                          
14
 Caplan, 2010; da Silva Meirelles et al., 2006 
15
 Locke et al., 2009 
16
 Fraser et al., 2006 
 
18
 Dominici et al., 2006; Zuk et al., 2002 
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3) immunophenotype20;  
4) differentiation capacity;  
5) immunosuppressive capacity21.  
 
Therefore, also considering the same embryonic mesodermic origin, it is likely to 
account ASCs as a peripheral MSCs lineage, supporting their use in several 
therapeutic applications. In particular, ASCs hold high potentials in orthopaedic 
tissue-engineering field, since they both promote osteogenesis at break sites and 
increase bone grafts integration22. Moreover, ASCs were shown to possess 
immunosuppressive and anti-rejection capacities; this finding rationally supports 
their allogenic use. 
 
MECHANISMS OF ACTION 
 
The therapeutic value of MSCs is based on a number of intrinsic characteristics, 
briefly listed and discussed below, which are shared by both BM-MSCs and ASCs: 
1) differentiation ability;  
2) trophic activity;  
3) immunomodulatory capacity  
 
 
                                                                                                                                                                                 
19
 Zuk et al., 2002 
20
 Peroni et al, 2008 
21
 Puissant et al., 2005;  
McIntosh et al., 2006 
22
 Tapp et al., 2008 
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1) Differentiation ability  
 
MSCs have been originally isolated and characterized to study their ability to 
differentiate into a broad spectrum of mesenchymal tissues, such as bone, 
cartilage, tendon, fat, muscle and marrow stroma. Firsts therapeutic applications 
were thus proposed, basing on the mere tissue engeneering logic that lineage-
oriented stem cells could reconstruct a specific site of application23. However, 
several pre-clinical studies demonstrated that MSCs-induced functional recovery of 
treated injured tissues occurs without a substantial differentiation of injected MSCs 
towards tissue-related phenotypes. Therefore, others mechanisms of action must 
be involved and differentiation should be considered as a secondary feature. 
 
New insights in MSCs pharmacodynamic depict this multipotent cell lineage as 
intelligent, injury-site specific, multidrug release system (Caplan, 2010). In fact, 
MSCs could be recluted by injured organs and, while chemoattracted by the 
proinflammatory cytokine tumor necrosis factor-α (TNF-α)24, home to sites of 
inflammation where they secrete a massive amount of bioactive agents, both 
trophic and immunomodulatory . 
 
2) Trophic activity 
 
It is considered “trophic activity” the MSCs ability to stimulate host regeneration 
trhough paracrine secretion of a serie of molecules that induce the following 
physiological responses: 
                                                          
23
 Wagner et al., 2009 
24Ponte et al., 2007 
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a) inhibition of apoptosis with consequent limitation of the damaged field;  
b) inhibition of scarring and fibrosis in the site of injury, thus reducing severe 
post-lesions fibrogenesis;  
c) stimulation of angiogenesis;  
d) stimulation of proliferation of tissue-specific regenerative progenitors.  
 
Trophic activity of MSCs represent a key feature in bone regeneration and graft 
survival. In fact, angiogenesis and consequent avalaibility of blood supply are 
crucial, both for reformation of new structural osseous tissue and for success of 
engineered scaffolds engraftment. 
 
In addition, MSCs-induced stimulation of tissue progenitors to divide and 
differentiate into functional regenerative units, represents one of the most important 
properties underlying organs regeneration. 
 
3) Immunomodulatory capacity 
 
MSCs are known to avoid allogeneic rejection (Ryan et al., 2005); powerful 
immunomodulatory and antinflammatory properties of this cell lineage are the most 
important pharmacological rationals justifying their allogeneic uses. Three broad 
mechanisms contribute to MSCs anti-rejection ability: 
 
a) MSCs are hypoimmunogenic themselves; even if there are still some 
controversial results about MSCs cell surface expression of major 
histocompatibility complexes (MHC), many researches suggest that these cells are 
12 
 
MHC-II negative (McIntosh et al., 2009; Ryan et al., 2005). Absence of MHC-II 
gives to MSCs the useful potential to escape host CD4+ T cells recognition;  
 
b) MSCs are able to suppress proliferation and cytokine secretion of natural killer 
(NK) cells by cell-to-cell direct interaction (Sotiropoulou et al., 2006);  
 
c) MSCs extensively secrete a wide range of bioactive molecules, which create a 
surrounding immuno-suppressive milieu. Prostaglandin E2 (PGE-2) was found to 
be a central effector of several MSCs-mediated effects on immune system; in fact, 
it has been shown that MSCs-secreted PGE-2 has powerful inhibiting activities on 
dendritic-1 (DC-1), T and NK cells proliferation and secretory profile (Aggarwal and 
Pittenger, 2005; Sotiropoulou et al., 2006). In the meantime, PGE-2 also increases 
DC-2 cells secretion of interleukin-10 (IL-10), which, in turn, suppresses the 
outcome of TNF-α and interferon-γ (IFN- γ), two of the most important 
proinflammatory cytokines25. Catabolites of tryptophan produced by MSCs, are 
also bioactive, since they act suppressing both CD4+ and CD8+ T lymphocyte 
subtypes activation.  
 
In brief, cumulative results show that any immunosurveillance cell coming into the 
range of MSCs will be suppressed. This feature grants MSCs several abilities, 
such as escaping host immuno-recognition, inhibiting immunosurveillance at the 
injury site and preventing autoimmune events to estabilish. Therefore, alloreactivity 
doesn’t seem to be a major problem for MSCs and their addition to a bone graft 
should protect it from the host immune system, enhancing its survival probabilities. 
                                                          
25
 Aggarwal and Pittenger, 2005 
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PRE-CLINICAL  STUDIES,  CLINICAL  TRIALS  AND  CURRENT  
APPLICATIONS  OF ADIPOSE-DERIVED MSCs 
 
As described above, therapeutic uses of ASCs are supported by two important 
characteristics of this cell lineage: regenerative properties and immunomodulatory 
activity. To date, proposed employments for ASCs in tissue repair and 
regeneration are quite impressive and can be listed following clinical application 
criteria. 
 
1) Musculoskeletal tissues regeneration;  
2) myocardial infarction;  
3) applications based on ASCs immunomodulatory properties;  
4) gastrointestinal diseases;  
5) urogenital system disorders;  
6) nervous system diseases;  
7) wound healing;  
8) plastic surgery and tissue reconstruction;  
9) other clinical trials.  
 
1) Musculoskeletal tissue regeneration 
 
Considering the adipose tissue mesodermal origin, application of ASCs to bone 
and cartilage defects is obvious, along with their uses in tendon and invertebral 
disk repair. 
Succesful outcomes in pre-clinical researches include: 
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a) repairing of calvarial defects, studied both in rat (26) and rabbit models (Dudas 
et al., 2006);  
b) repairing of rats cleft palatal bone defects27;  
c) repairing of rabbits tibia proximal epiphysis28;  
d) repairing of mice cartilage defects using a human ASCs (hASCs) tissue-
engineered cartilage29;  
e) primary tendon repair in an in vivo tendon injury model30;  
f) intervertebral disc regeneration in small animals model, such as rats and 
rabbits and in larger animal models, such as goat and canine ;  
g) facilitation of spine fusion in rats using allogeneic ASCs isolated both from 
rat and from human adipose tissue.  
 
For what it concerns data on humans, to date licterature decscribes two important 
case reports and and one ongoing clinical trial (NCT01218945). 
 
The first is a report of a 7-year-old girl suffering from a widespread calvarial defects 
after severe head injury31. Due to the limited amount of autologous cancellous 
bone, autologous ASCs were purified and applied to the calvarial defects toghether 
with autologous fibrin glue. Three months after the reconstruction, CT-scan 
showed new bone formation and almost complete calvarial continuity. 
 
                                                          
26
 Cowan et al., 2004; Yoon et al., 2007 
27
 Conejero et al., 2006 
28
 de Girolamo et al., 2010 
29
 Dragoo et al., 2003 
30
 Uysal and Mizuno, 2009 
31
 Lendeckel et al., 2004 
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The second reports the orbital floor reconstruction of a 65-year-old male patient 
who had undergone a hemimaxillectomy due to a large keratocyst. The large 
defect was reconstruct with a titanium cage, filled with autologous ASCs and 
betaTCP, that was previously inserted for 6 months in a pouch prepared in the 
patient’s left rectus abdominis muscle. Success of this reconstruction is mainly to 
ascribe both to bony neotissue and good vascularization of the titanium scaffold; 
this result also indicates that ASCs promote intense neovascularization, a crucial 
feature for grafts survival. 
The clinical trial number NCT01218945 concerns the development of engineered 
synthetic bone grafts, preloaded with hASCs, to repair large osseous defects. 
 
 
2) Myocardial infarction 
 
Numerous studies in animal models have investigated the ASCs potential for 
treating myocardial infarctions and chronic heart failure32. ASCs mainly exert their 
myocardial regenerative effect through secretion of trophic soluble factors33. Again, 
paracrine activity seems to play a key role in ASCs-mediated therapeutic 
properties. 
 
In humans, there are two ongoing phase I clinical research studies (NCT00442806 
and NCT00426868). 
 
 
                                                          
32
 Hwangbo et al, 2010; Mazo et al., 2010; Bai et al., 2010; Valina et al., 2007 
33
 Bai et al., 2010 
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3) Applications based on ASCs immunomodulatory properties 
 
The capacity of ASCs to regulate a wide spectrum of inflammatory mediators, 
offers a precious therapeutic tool to treat several clinical conditions needing 
pharmacological immunosuppresion. 
 
Pre-clinical studies include: 
a) treating of mice experimental arthritis with hASCs  
b) treating of mice experimental allergic rhinitis with allogenic mASCs;  
c) anti-rejection activity in organ transplantation; in a rat liver transplantation model, 
allogeneic ASCs significantly alleviated acute rejection. This field of application 
holds great promises for the future of MSCs cell lineages, however, to date, sudies 
are limited to animal models;  
 
In humans, an encouraging result comes from a study reporting allogeneic infusion 
of hASCs in six patients who have developed chronic and extensive graft versus 
host disease (GvHD), after haematopoietic stem cell transplantation34. In addition, 
allogeneic infusion of hASCs has also been approved to be used for the same 
application in an ongoing phase II clinical trial (NCT01222039). 
 
4) Gastrointestinal diseases 
hASCs have also been shown to be a valuable opportunity to treat patients with 
intractable enterocutaneous35, perianal  and rectovaginal fistulas36, as a result of 
Crohn’s disease. Four related clinical trials are reported: 
                                                          
34
  Song et al., 2007 
35
 Garcia-Olmo et al., 2009A 
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a) safety and efficacy study of autologous cultured hASC for the Crohn's fistula, 
phase I, completed (NCT00992485 );  
b) safety and efficacy study of autologous cultured hASC for the Crohn's fistula, 
phase II, ongoing (NCT01011244);  
c)allogenic hASCs derived from lipoaspirates for the treatment of recto-vaginal 
fistulas associated to Crohn`s disease, phase I and II, ongoing (NCT00999115);  
d)treatment of fistulous Crohn's disease by implant of autologous hASCs, phase I 
and II, ongoing (NCT01157650)  
 
Interestingly, no pre-clinical studies are available for the same indications. 
 
5) Urogenital system disorder 
ASCs regenerative properties have also been applied in several urology preclinical 
researches: 
a) treatment of rats stress urinary incontinence 37;  
b) rats and rabbits bladder reconstruction;  
c) treatment of erectile dysfunction in obese type 2 diabetic;  
 
In addition, one case report has been recently published, regarding two patients 
that receive periurethral injection of autologous ASCs for urinary incontinence, due 
to post-radical prostatectomy (Yamamoto et al., 2010). This prelminary study 
showed that periurethral injection of autologous ASCs is a safe and feasible 
treatment modality for stress urinary incontinence in humans. 
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6) Nervous system diseases 
 
As shown by pre-clinical results, ASCs trophic activity improves nervous system’s 
cell replacement and tissue regeneration. Proposed field of application include: 
 
a) improving of brain recovery in rat stroke models -hASCs-;  
b) improving of motor function in rat models of spinal cord injury -autologous 
rASCs-;  
c) repairing of injured rats peripheral nerves –hASCs-.  
 
In human, a safety/efficacy phase I and II clinical study is evaluating the feasibility 
of regenerative therapy with autologous ASC, administered intravenously, in 
patients with secondary progressive multiple sclerosis who do not respond to 
regular treatments (NCT01056471). 
 
7) Wound healing 
Therapeutic potential of ASCs in wound healing has also been investigated. 
 
In rats mitomycin C-treated healing-impaired wounds, local application of 
autologous ASCs can induce significant wound healing acceleration38. 
 
Clinical outcome potential was also confirmed in humans. Twenty patients being 
treated for the side effect of radiotherapy, with severe symtpoms, received 
autologous ASCs via repeated hypoinvasive computer-assisted injections; this 
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clinical approach led to a systematic improvement or remission of symptoms in all 
evaluated patients39. 
 
8) plastic surgery and tissue reconstruction 
 
Engineer of adipose tissue finds one of its major expressions in plastic surgery and 
in tissue reconstruction fields. Four clinical trials are currently reported: 
 
a) phaseIV post-marketing study evaluating the transplantation of autologous fat 
enriched with ASCs, in patients with functional and cosmetic breast deformities 
post lumpectomy (NCT00616135);  
b) completed phase II and III clinical trials evaluating the safety and efficacy of 
autologous adipocytes and ASCs, differentiated towards the adipocytes phenotype, 
to treat depressed scars (NCT00992147);  
c) phase I study determining the safety of the autologous ASCs transplantation 
in the treatment of lipodystrophies (NCT00715546);  
 
d) completed phase III clinical trial investigating safety and efficacy of 
autologous ASCs for the closure of perianal fistulas in patients without Crohn´s 
disease (NCT00475410).  
 
 
9) Other clinical trials 
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For what it concerns ASCs-based ongoing clinical trials, others four human 
applications are currently under investigation: 
 
a) phase I and II clinical studies determining whether intravenous administration of 
autologous adipose ASCs is safe and beneficial in patients with type 1 diabetes 
(NCT00703599);  
b) phase I and II trials determining whether intravenous administration of 
autologous ASCs would account a benefit in the types 2 diabetics management 
(NCT00703612);  
c) completed phase III clinical trial investigating safety and efficacy of 
autologous ASCs for the closure of perianal fistulas, in patients without Crohn´s 
disease (NCT00475410);  
d) phase I and II studies evaluating safety and feasibility of regenerative 
therapy with autologous ASCs, administered intramusculary, in patients with critical 
leg ischemia (NCT01211028).  
 
SAFETY CONCERNS 
 
The use of adult MSCs -including ASCs- in cell-based therapies is considered 
safer and more functional than use of either hESCs and iPSs. In fact, MCSs are 
immunocompatible and don’t require genetic manipulation; moreover, their clinical 
employment doesn’t elicit any ethical controversy. 
ASCs are known to undergo malignant transformation during protracted culture in 
vitro (20-30 passages); however, for clinical applications, it is unlekely that there 
will be a need for cultures longer than one passage. 
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Finally, no adverse and rejection reactions were reported in pre-clinical and clinical 
trials, thus confirming the high safety rate of ASCs. 
 
Finally it can ba considered that MSCs are the major candidates for the future of 
regenerative therapies. Among several proposed putative sources of MSCs, 
adipose tissue has been proven to be the most promising because of three 
intrinsinc features: high yield of stem cells, avalaibility and easy harvesting. In 
addition, it has been demonstrated the ability of ASCs to suppress specific aspects 
of immune system, toghether with pre-clinical and clinical studies reporting no 
rejection -or adverse effect- for allogeneic treatment. The possibility to use 
unmatched allogeneic ASCs implies that a single lot of cells, derived from one 
donor, could be transplanted into multiple patients. There are two consequent 
advantages in that: reduction of the quality control costs and benefit for treated 
patients, that would be always transplanted with young and healthy selected cells. 
 
Abilities of adult ASCs in promoting bone formation and grafts survival are well 
established. Even though, focus of investigations surrounding ASCs applications in 
spine fusion is still limited40. However, the physiological characteristics of ASCs 
indicate that this cell lineage possesses exciting potentials in the stem cell-based 
regenerative therapies. For this reason, optimization of both cell growth and choice 
of scaffold will offer succesful surgical outcomes in several orthopaedic 
applications. 
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Chapter 2 
Cell separation 
 
 
 
Overview on cell separation 
 
 Cell separation is a powerful tool, which is widely used in many strands of 
biological and biomedical research and in clinical therapy. For research, the ability 
to sort cells into distinct populations enables the study of individual cell types 
isolated from a heterogeneous starting population without (or with greatly reduced) 
contamination from other cell types. This technology underpins many discoveries in 
cell biology and is further enabling research in areas as diverse as regenerative 
medicine, cancer therapy and HIV pathogenesis. 
In terms of clinical usage, therapeutic cell separation allows for the introduction of 
enriched cell populations to a patient with a clinical need for those cells, for 
example, separation of leukocytes by aphaeresis or enrichment of haematopoietic 
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stem cells by immunomagnetic separation41 42. It also enables the enumeration of 
cells within an individual’s blood system and can aid repopulation of the immune 
system, for example, in multiple sclerosis patients who have undergone 
immunoablation treatment. 
Currently, most regenerative treatments based on cell separation are restricted to 
tissues such as blood and bone marrow43. Recently, however, advances in stem 
cell therapy, tissue engineering and regenerative medicine are showing the 
potential for clinical cell-based therapies using cells derived from a variety of 
tissues, such as adipose and intestine. The use of highly selective cell separation 
procedures in clinical cell-based treatments has the potential to improve the quality 
of repair and the subsequent clinical outcome. Because of this potential, there is an 
increasing usage of these methodologies in the fields of tissue engineering and 
regenerative medicine, which has resulted in an increasing number of researchers 
using, or wanting to use, cell separation technologies. These researchers are 
drawn from a diverse range of backgrounds, not all of whom are necessarily based 
in biology. Indeed, the increasing demand for cell separation in multiple disciplinary 
research fields is not restricted to tissue engineering and regenerative medicine; 
cell sorting is also being used in many other areas such as biochemistry, electrical 
engineering, physics and materials science. 
A multitude of cell separation techniques currently available to researchers are 
based on three core themes: density, adherence and antibody binding, with many 
points of crossover between these different themes. New techniques incorporating 
microfluidics combined with a variety of cellular properties are also in development. 
                                                          
41
 Handgretinger R, Lang P, Schumm M, et al. Bone Marrow Transplant 1998; 21: 987–993 
42
 To LB, Haylock D, Simmons PJ, et al. The biology and clini-cal uses of blood stem cells. Blood 
1997; 89: 2233–2258 
43
 Stamm C, Westphal B, Kleine H-D, et al. Lancet 2003; 361: 45–46 
24 
 
Despite the differences between different cell separation techniques, they share 
common problems and pitfalls, which can at best hinder research progress and at 
worst give rise to erroneous data. Many of these technical problems and pitfalls are 
only applicable to certain techniques, whereas others are universal regardless of 
the method of separation. Other difficulties can arise in the experimental planning 
stage, where there can be a lack of understanding in identifying appropriate 
controls. Finally, there is a potential lack of clarity in the terminology used around 
cell separation methods, which can lead to confusion and a misunderstanding of 
the analytical measures required. 
This review is written taking cognisance of the diversity of backgrounds and 
expertise of those researchers wishing to use cell sorting methods. The aim is not 
to produce a detailed step-by-step guide for each methodology but to offer 
potential solutions when common difficulties arise and provide clarity in areas of 
ambiguity related to experimental preparation and terminology. 
 
 
Cell separation techniques 
A large variety of cell separation methods are currently commercially available, 
these are predominantly based on three methodologies: adherence, density and 
antibody binding. New techniques are being developed that utilise microfluidic 
technologies and take advantage of a variety of cellular properties such as 
elasticity in response to acoustic waves and membrane polarisation in a non-
uniform electric field44. 45 However, these techniques are mostly still experimental 
and not yet available commercially for research. The choice of separation method 
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depends upon a variety of factors, and each methodology has benefits and 
drawbacks that affect its applicability in a given situation. In this section, we will 
briefly outline the three overall methodologies with specific examples of each. 
Adherence 
Techniques that utilise cellular adherence are some of the most simple methods 
used for cell separation and are routinely used when isolating cells from digested 
or explanted primary tissues (Figure 1.2). An example of simple cell separation by 
adherence is the isolation of dental pulp stromal cells from whole digested dental 
pulp. In this technique, enzymatically digested dental pulp is filtered and plated 
directly onto tissue culture plastic, and following a period of culture, the adherent 
stromal cells are passaged.46 This technique benefits from being very simple and 
cheap, but it is not at all specific and relies on the cells of interest adhering and in 
some instances rapidly proliferating to outcompete other adherent cells in the 
suspension, such as neurons and monocytes. Adherence can also take time 
leading to some uncertainty as to the success of a separation. Recently, 
techniques based on cell adherence, such as differential binding of cells to polymer 
brushes of varying lengths, grafted to glass surfaces, have been developed and 
these are currently being refined.However, despite this progress, current uses of 
adherence sorting are mostly only applicable when cell purity is not of concern and 
isolation of various subpopulations is not required. 
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Figure 1.2. Diagram detailing cell separation by plastic adherence. (a) Whole tissue 
is disrupted into a cell suspension by enzymatic or mechanical means or a 
combination of both (separations of blood or bone marrow aspirate do not require 
this step). (b) Following disruption, the cells can be passed through a filter to 
remove cell clumps (c) giving a single-cell suspension, which will be added to (d) 
an adherent surface, and after a period of culture, (e) adherent cells can be 
observed. 
 
 
 
Density 
Density-based techniques are now mostly based on the use of centrifugation, 
although historically sedimentation-based methods have been employed47 
.Techniques based on centrifugation are commonly used in many laboratories and 
are also routinely used clinically. The ability to sort large numbers of cells based on 
their density, relative to a graduated separation medium (usually sugar based), 
makes these techniques particularly applicable for separations involving the use of 
blood (Figure 1.3), which contains 4 × 109 to 6.5 × 109 cells/mL. Indeed, the most 
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commonly used clinical cell separation method is aphaeresis of whole blood to 
isolate mononuclear cells for treatment of a variety of conditions, including 
leukaemia48. However, despite the large-scale use of density-based methods, 
there are still problems with specificity as the differing densities of different cell 
populations are, in some instances, not large enough to be able to separate out 
individual cell types. These problems can be overcome by performing repeated 
centrifugations using differing concentrations of centrifugation medium and differing 
angular velocities. By using these techniques, it is possible to isolate different cell 
types from a complex mix, including disrupted solid tissues (Figure 1.4) such as 
mouse liver. However, although technically feasible, this is still challenging to 
perform with high specificity. As such, centrifugation methods are generally used if 
specificity is not absolutely necessary, as in aphaeresis, or as a pre-enrichment 
stage to remove cells like red blood cells and platelets. 
Another density-based method used in laboratory separations is rosetting, which 
works as a combination between antibody binding and density methods. In this 
method, unwanted cells are labelled with antibodies that subsequently form 
complexes with erythrocytes, creating immunorosettes that are much denser than 
the mononuclear cells of interest. Following centrifugation, these rosettes, 
containing the labelled unwanted cells, pellet with erythrocytes leaving purified 
target cells in the mononuclear cell phase.21 
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Figure 1.3 : Diagram detailing whole blood cell separation by density gradient 
centrifugation. (a) Initially, whole blood is diluted with saline buffer, and (b) this is 
then carefully layered on top of the centrifugation medium contained in a conical 
tube avoiding any mixing of the two phases. (c) Following centrifugation, at the 
appropriate velocity without braking, distinct phases can be observed; 1 – plasma, 
2 – interphase containing mononuclear cells, 3 – centrifugation medium and 4 – 
erythrocytes and granulocytes; cells can then be aspirated from the interphase. 
 
 
Figure 1.4: Diagram showing separation of solid tissue–derived cells by density 
gradient centrifugation. Tissues are (a) dissociated and (b) filtered to give (c) a 
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single-cell suspension. (d) This suspension is carefully layered over a 
centrifugation medium avoiding mixing to give (e) two distinct phases, which can 
then be centrifuged to give (f) a cell-rich interphase between the centrifugation 
medium and the cell suspension buffer. (g and h) It is possible to isolate different 
cell fractions by removing cells from the supernatant or the interphase and then 
recentrifuging them at different concentrations of centrifugation medium and 
angular velocities until the desired fractions are obtained. 
Methods that sort cells by density are useful techniques to employ when working 
with tissues that contain a large number of unwanted cells, for example, blood, 
bone marrow and adipose tissue. This can be either for the isolation of a 
heterogeneous mix of cells, which can then be used experimentally, or as a pre-
enrichment step prior to sorting by other methods. 
 
Antibody binding 
Antibody-binding methods generally refer to the commonly used techniques of 
fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting 
(MACS)49 50.51 Both technologies utilise the same cellular properties for separation, 
namely, cell surface antigens against which antibodies are raised. FACS 
separation relies on the conjugation of fluorescent labels to these antibodies, 
whereas MACS uses conjugation to iron oxide containing microbeads. Following 
binding of conjugated antibodies, FACS and MACS proceed down different routes. 
FACS separation is achieved by laser excitation of the bound fluorophores, with 
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excitation above a threshold level signalling the corresponding cell to be separated 
(Figure 1.5). 
MACS requires the cells to be placed in a magnetic field; unlabelled cells are 
eluted, and labelled cells are retained in the field until they are removed from the 
magnet, giving the separated populations (Figure 1.6). 
 
Figure 1.5 Diagram showing cell separation by FACS. Fluorescently labelled single cells 
from solid or fluid tissues, filtered to remove cell aggregates, are channelled to give a 
continuous stream of individual cells; (b) these cells then pass through a light source or 
laser, and the signature of each cell is detected. From this detection, the cells will be 
determined to be above or below a designated threshold value, and it is decided whether 
to collect or not collect each cell. (c) This is achieved by electrically charging the droplet 
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each cell is contained within and (d) then by passing it through charged deflector plates 
that deflect the cells to the appropriate collection tubes. 
FACS: fluorescence-activated cell sorting. 
 
 
Figure 1.6: Diagrams showing the common methods used for magnetic cell separation. (a) Tube-
based separation where a magnetically labelled cell suspension held in a conical tube is placed in a 
(1) magnet causing movement of labelled cells to the sides of the tube towards the magnet. This 
tube is then (2) inverted (or aspirated), allowing removal of the non-labelled cells before (3) 
resuspension of the labelled cells and removal from the magnet giving (4) a dispersed suspension 
of labelled target cells. (b) Column-based separation where a magnetically labelled cell suspension 
is injected into a column held within a magnet, (1) cells then flow through the column and (2) 
labelled cells are retained, whereas unlabelled cells are washed out. (3) Following the removal of 
unlabelled cells, the column is removed from the magnet, and suspension buffer is forced through 
the column by plunger giving labelled target cells in suspension. 
 
 As such, a key difference between MACS and FACS is that MACS can be seen as 
a bulk method, there is no individual cell analysis, and magnetically tagged cells 
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are retained and non-tagged cells are eluted. FACS, however, analyses each 
individual cell, which can be tagged with multiple antibodies, whereas MACS is 
restricted to individual markers (although some kits use enzymatic removal of the 
microbeads, allowing the cells to be relabelled with a subsequent antibody). This 
individual cell analysis means that while FACS can be more specific, it is 
significantly slower than MACS. Sorting that takes several hours by FACS can be 
achieved in less than 1 h by MACS. 
There are other techniques, in addition to FACS and MACS, that utilise antibody 
binding to enable cell separation, an example of which is rosetting as previously 
mentioned. However, this is a relatively old technique, and there are many new 
technologies being developed, which use antibody or cell–ligand binding as the 
basis for separation. For example, antibodies, immobilised to polymer surfaces, 
have been used in a microfluidic system to capture circulating tumour cells from 
whole blood with subsequent release and enumeration. Columns have also been 
developed with antibody-immobilised surfaces to enrich osteoblastic cells based on 
CD34 binding. Polymer cryogels with large interconnected pores and surface-
immobilised protein A ligands have been used to isolate antibody-labelled CD34+ 
umbilical cord blood cells in an affinity chromatography–based separation.52 Other 
methods in development include magnetophoresis, DNA aptamer binding53 and 
aqueous phase partitioning54. However, despite the variety of antibody-based 
methods, for the purposes of this review, FACS and MACS will be focussed on due 
to the experimental nature of these newer techniques. 
Antibody-based methods of separation are currently the gold standard for the 
selection of individual cell populations, and both FACS and MACS can be used to 
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isolate cell populations to high purity. Despite this, there are still some problems 
with FACS and MACS such as the reliance on cell surface markers, which, for 
most researchers, limits separations to those markers for which antibodies are 
commercially available. It can also cause problems if the cell type of interest does 
not have unique markers, making the isolation of a homogeneous population 
difficult. For example, mesenchymal stem cells (MSCs) express markers 
associated with many other cell types such as CD90, which is also expressed by 
primitive haematopoietic stem cells. In addition, the isolation of a viable 
homogeneous population of cells that contain a unique intracellular marker can 
also be problematic, as the permeabilisation steps required to stain the marker can 
damage cell membranes leading to cell death. 
Lab-on-a-chip methods 
In addition to the traditionally used methodologies for cell separation are several 
new lab-on-a-chip techniques that operate on a microfluidic scale and utilise a 
multitude of cellular characteristics to isolate different cell populations in a label-
free manner. These techniques are mostly still in the experimental stage, but their 
development demonstrates the variety of possible ways to separate cells, and they 
are extensively reviewed by Gossett et al.55 Examples of label-free separation are 
the use of micro-scale filters or pillars that separate cells based upon size and 
membrane deformability, as larger cells are prevented from navigating through the 
filter leading to cell separation.56 Field flow fractionation (FFF) can be used to 
separate cells along the length of a microfluidic channel by a combination of the 
parabolic flow within the channel and an external field, such as an electric field or 
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gravity. With FFF, particles that are more greatly affected by the external field are 
forced closer to the channel wall, which is moving more slowly than the centre of 
the channel and contains more weakly affected particles. Therefore, cell separation 
occurs because of the effect of the force on the cells and the speed of elution 
based on the cells’ location in the microfluidic channel.57 Acoustophoresis 
separates cells based on membrane deformation or elasticity and occurs when a 
high-pressure sound wave interacts with a cell. This interaction can cause 
membrane deformation to differing degrees based on the cell’s density and size 
and leads to the cells being positioned in different parts of the microfluidic channel 
and therefore able to be separated. Dielectrophoresis can lead to cell separation 
due to the differential polarisation of particles within a non-uniform electric field. 
This dipole effect depends on factors such as size and protein content and leads to 
the attraction or repulsion of the cell away from or towards an electrode. Due to 
differences in these factors between different cells, it is therefore possible to exert 
different effects on different cell types within the same field and allow for cell 
separation. 
Label-free lab-on-a-chip isolation methods have great potential to improve cell 
sorting methods both in a research environment and clinically. However, there are 
still potential problems associated with these techniques, many of which are 
general cell sorting problems, which can be applied to the commonly used 
techniques such as cell clusters, and others that are technique specific. One of the 
largest problems these techniques currently face is resolving the differences 
between cell types; for example, with dielectrophoresis, it can be difficult to discern 
the differences between target and non-target cells. However, perhaps the greatest 
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challenge these techniques face is showing great enough efficacy while 
overcoming the challenges associated with currently used methods. 
Overall, the choice of cell separation methodology is very much dependent upon 
the initial cell source, the characteristics of the desired cell type and its required 
purity. Adhesion-based techniques are useful if there is little requirement other than 
the isolation of adherent cells, and the cell of interest will, if necessary, outcompete 
other cell types. Centrifugation techniques are useful when dealing with samples 
with large cell numbers, such as blood, but where specificity is not essential, and 
are also useful as a pre-enrichment step prior to other separation methods. 
Antibody-mediated separation methods are the gold standard techniques currently 
available as they can be used to isolate specific cell populations. However, speed 
can be an issue, as can costs. Potentially, lab-on-a-chip methods will overcome 
some of the limitations in the currently used techniques, but, as yet, these are 
experimental and not accessible to the majority of the researchers performing cell 
sorting. 
 
Clinical cell therapy 
The majority of separations currently performed for clinical cell therapy use cells 
isolated from tissues such as bone marrow and blood. These separations isolate 
the mononuclear cells, including the stem cell fraction, and can be used to 
recapitulate the haematopoietic system of a patient suffering from, for example, 
chronic myeloid leukaemia, following immune ablation therapy. These separations 
mostly utilise systems based on centrifugation, such as aphaeresis, as these 
technologies allow for the isolation of the large numbers of mononuclear cells 
needed for cell transplantation relatively quickly. MACS can also be used for cell 
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therapy, and the clinically approved MACS-based systems use the same 
technology as research-grade magnetic sorting; however, these systems are 
closed and use reagents and fluidic tubing produced under good manufacturing 
practice (GMP) conditions.58 Use of MACS for clinical cell sorting allows for greater 
specificity than can be achieved by centrifugation; however, per patient, MACS is 
more expensive than aphaeresis, and so it is used in circumstances where 
specificity of the isolated cells is important. 
Standard FACS-based systems are not in clinical use for cell therapy, although 
some flow cytometers can be used for clinical diagnostics59. This is in part due to 
the difficulty in developing single-use sterile fluidics, the possibility of cross-
contamination should multiuse fluidics be employed and problems with batch-to-
batch consistency. There are currently methods utilising closed system optical 
separation in development, but these are not yet in widespread clinical usage. 
Clinical cell separation is an established field, but it has strict requirements, and 
there are challenges and difficulties to overcome. The major requirement is to 
ensure that a consistent, sterile cell population is isolated. Microbial contamination 
of cell separation products could lead to the infection of the recipient patient, who, 
in many instances, will be immunocompromised and unable to fight the infection. It 
is therefore imperative that clinical cell separation products are produced under 
strict GMP conditions with stringent batch testing. Consistency of the isolated cell 
population is also very important so as to ensure that the recipient receives the 
required cell transplant. In addition, rigorous tissue typing should be performed 
prior to transplantation to avoid human leukocyte antigen (HLA) mismatch and 
prevent problems such as graft-versus-host disease. 
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At this time, the major challenge for clinical cell separation is the robust isolation of 
rare cell populations with multiple surface markers from a large initial pool of cells. 
Currently, technologies based on centrifugation allow for the isolation of cells from 
a large initial cell number, and technologies based on MACS can isolate specific 
populations of cells; however, these technologies use single markers meaning that 
cells of interest with two or more markers cannot be specifically isolated. 
Development of high-speed optical cell sorters holds great promise, as these 
systems could have the speed of an MACS-based system, but with the specificity 
of an FACS system allowing for more than one parameter to be selected. 
 
Considerations for experimental design 
Initial planning and design is key for any experimental strategy, including cell 
separation, where many factors must first be considered. These factors impact 
different stages of the separation procedure, but all share a basic set of preliminary 
requirements. These are the need for a detailed understanding of the cell and 
tissue types of interest, knowledge of the potential techniques available and the 
ability to select the correct methodology to yield the desired cell population. 
The reason for this required level of understanding is that one cell separation 
method may be more suitable than another for achieving a given outcome, and 
different cells react differently to the same conditions. Current methods for cell 
separation generally offer a balance between purity and recovery. It is therefore 
important that the separation protocol is designed with this in mind and tailored to 
suit the desired outcome. For example, if a large number of cells are required, then 
percentage enrichment may need to be sacrificed; alternatively, for a highly 
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enriched population, the trade-off may be low numbers recovered. Factors to be 
considered when designing a cell separation strategy are discussed below. 
 
Cost 
Cost is a design constraint that is relevant to most separation experiments. Cell 
separation can be a potentially expensive technology depending on the strategy 
selected. It may therefore be important to devise a strategy that is not prohibitively 
expensive by employing cost-saving measures. For example, FACS is a very 
accurate technique, but it can be slow when sorting rare cells from whole blood, 
and this consequently increases the running time on the instrument and thus the 
expense. A way of reducing this time would be to perform an initial erythrocyte lysis 
step or density gradient centrifugation to remove the erythrocytes, leaving only the 
mononuclear cells to sort.60 Pretreatment of a sample can thus reduce overall cost 
and should be considered where cost is an issue. 
 
Methodological difficulties 
There are several key technical considerations that must be taken into account 
before performing a successful cell separation, some of which are universally 
applicable, while others are more specific to immunomagnetic and immuno-
fluorescent cell separation. Figure 6 gives an overview of potential technical 
problems at each stage during the separation process. 
The more universal considerations relate to the quality of the cells, which are being 
separated, and specifically to the cell isolation process. Antibody-mediated 
separations also have considerations relating to antibody binding. There can also 
be specific idiosyncratic problems associated with different commercially available 
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cell separation products such as incubation temperature and supernatant removal, 
but it is not within the remit of this review to discuss these. Any specific technical 
issues is best dealt with by the company responsible for the product. 
Cell isolation and preparation are essential prerequisites when sorting cells but can 
be the cause of many technical difficulties when resulting suspensions contain 
clusters of cells and/or a high proportion of dead cells. For the purposes of this 
review, we are defining a cell cluster as an association of two or more cells. Cell 
clusters can arise when working with both solid tissue- and blood-derived cells due 
to incomplete dissociation or post-dissociative association/aggregation. The 
presence of cell clusters can result in reduction in isolated cell purity due to co-
isolation of non-target cells that are conjoined with the cells of interest or loss of 
target cells due to their binding with cells that are removed from the suspension as 
part of the separation process. 
Currently available strategies for cell separation can yield highly enriched cell 
suspensions. However, there are potential problems that can impair the overall 
quality of the separation, and these need to be recognised by the increasingly 
interdisciplinary user base and addressed where they arise. In addition, 
experimental planning and terminology need to be carefully considered. 
In the initial experimental design and planning stages, it is important to understand 
what outcomes are going to be assessed, that is, how are purity, recovery and 
viability being measured? It is important to identify the characteristic which purity is 
being measured against, which population the recovered cells are being compared 
to and which measure of viability is being assessed. If these terminological 
ambiguities are defined prior to beginning the experimental regimen, it can make 
identifying technical problems easier. 
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A thorough knowledge of the cell suspension and the cell type to be isolated can 
vastly improve the quality of a separation. This is particularly important for cell 
separation based on antibody binding. It is also important to collect samples at key 
points during the separation process so that the efficiency of the separation can be 
assessed. This point is related to the terminological considerations, as these data 
are required to determine the purity, recovery and viability. Perhaps the most 
important preparatory step prior to separation is the storage of the starting tissue. 
The key aspect with this is speed of tissue processing, with dissociation and cell 
separation immediately following tissue excision being greatly preferred. If this is 
not possible, then various means can be employed to reduce tissue necrosis, the 
most important of which is temperature. 
Technically, there are several factors that can compromise the quality of a cell 
separation and subsequently the overall data acquired. These factors can be 
distilled down to two main problems: clusters of cells and false-positive cell sorting. 
Both of these problems have multiple causes, some of which overlap. The general 
problems are incomplete tissue digestion, re-establishment of cell–cell contacts, 
release of DNA by dying cells, non-specific antibody labelling of dead cells and 
non-specific antibody binding to the FcR. None of these technical problems are 
insurmountable, but they can lead to significant problems without knowledge and 
awareness of the issues together with appropriate measures taken to address 
them. 
Overall, it is hoped that this review clarifies terminology, provides guidance to 
experimental set-up and gives reasons for and solutions to potential problems that 
can arise during the process of cell separation. We hope that we have achieved 
our aim of providing the user with an understanding of why certain terminology is 
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used and what it means, why certain aspects of planning and set-up are key to 
successful separations and what the main technical difficulties that can arise during 
the process are and how they can be resolved. 
 
FIELD FLOW FRACTIONATION 
Novel tagless separation techniques have emerged as alternatives to current 
methodologies for stem cells isolation. The most reported examples of these 
innovative technologies are dielectrophoresis (DEP), aqueous two phase systems 
and field flow fractionation (FFF). All of these methodologies do not require the use 
of a molecular tag, eliminating incubation times and often the label removal or 
detaching step. A relevant feature of this group of methods is their feasibility to be 
implemented at microscale (lab-on-chip).  
FFF is a chromatographic-like, soft impact separation method that performs 
partition based on mass, size, charge, density, shape, and rigidity. Separation is 
achieved within a capillary channel by the combined action of a mobile phase in 
laminar flow and a field that is applied perpendicularly to the flow. According to 
their physical characteristics, cells are distributed at different positions within the 
flow profile resulting in different elution times, and fractions can be collected 
separately.61 Different types of field have been used in FFF: gravitational field flow 
(GrFFF), centrifugal sedimentation field flow (SdFFF) and dielectrophoretic field 
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J. C. Giddings (Eds.), Field-flow fractionation hand-book, chapter 29 (pp. 471–486). New 
York: Wiley-Interscience. 
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flow (DEP).13 DEP-GrFFF has been also scaled up to process up to 1 million cells 
per run, which can be compared to the performance of the FACS but with 
significant lower cost.  
Elution mode in FFF 
Normal mode 
The normal FFF mode drives the elution of macromolecules and submicrometer 
particles. As the macromolecules or particles that constitute the sample are driven 
by the field toward the accumulation wall, their concentration increases with 
decreasing distance from the wall (Figure 2.1a). This creates a concentration 
gradient that causes sample diffusion away from the wall. When these two 
opposite transport processes balance, the sample cloud reaches a characteristic 
average elevation from the wall. The lower the molar mass or size of the sample 
component, the greater the component cloud elevation, the deeper the cloud 
penetration into the faster streamlines of the parabolic flow profile and the shorter 
the time required by the component to exit the channel. Retention time in normal 
FFF is therefore shorter for lower molar mass or size.  
Steric and hyperlayer mode  
If the sample components are micron-sized particles, their diffusion away from the 
wall is negligible. Particles are in fact driven by the field directly to the accumulation 
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wall. Particles of a given size form a thin layer of a given thickness, hugging the 
wall. 
Larger particles form thicker layers that penetrate into faster streamlines of the 
parabolic flow profile, and they are eluted more rapidly than smaller particles. This 
is just the opposite of normal mode elution: it is then referred to as a reversed 
mode. This elution mode is in fact governed by the physical (steric) barrier of the 
accumulation wall, so is called ‘steric’ (Figure 2.1b). Retention in steric FFF then 
depends only on particle size. During elution, however, the micron-sized particles 
make very little contact with the wall. Instead, their moves toward the wall are 
opposed by mobile phase flow-induced lift forces (Figure Ic, green arrows). When 
particles are driven from the wall by a distance that is greater than their diameter, 
the retention mode is called hyperlayer (Figure 2.1c). Retention in hyperlayer mode 
is still reversed with respect to particle size but it also depends on thevarious 
physical features of the particles, which will have a varying influence on the 
intensity of the flow-induced lift forces.  
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Figure 2.1. Most-frequently-used FFF 
operating modes. Different 
mechanisms of separation for 
particles of different size. (a) Normal, 
(b) steric and (c) hyperlayer mode.  
 
 
 
 
 
45 
 
Non-equilibrium, Earth gravity-assisted dynamic 
fractionation (NEEGA-DF) 
 
GrFFF has been used to sort different human stem cells and to enrich 
leukapheresis samples from healthy human donors. 62Due to its high simplicity and 
biocompatibility, GrFFF poses no technical issues for the fractionation of cells 
under easy sterilization conditions and the fractionation device, once used, may be 
disposed. However, application of GrFFF method to adherent cells requires cell 
sedimentation at the accumulation wall, which tends to cause cell adhesion to the 
wall and cell-cell aggregation/stacking. This can drastically reduce cell recovery, 
and also affects cell functionality after fractionation. We have developed a method 
based on a novel modification of the GrFFF process. The method is named Non-
equilibrium, Earth gravity-assisted dynamic fractionation (NEEGA-DF). NEEGA-DF 
does not require cell sedimentation at the accumulation wall.63 Compared to 
GrFFF, in NEEGA-DF cell contact and adhesion with the separation device are 
avoided by in-flow injection, by the absence of stop-flow cell sedimentation, and by 
using elution flow rate values able to generate hydrodynamic forces that are 
intense enough to lift and keep cells away from the channel wall. Since during 
separation cells are suspended in a fluidic condition, they acquire features that 
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may be different from their native, adherent state. The fractionation process is 
therefore based on the differences in cell features that are dynamically acquired 
during flow-assisted fractionation under the combined action of the flow stream, the 
gravitational field, and the hydrodynamic lift forces. The flow rate values applied 
guarantee low shear stress on cells. After fractionation is completed, cells can 
return to the adherent state, and the native physical features are fully restored. 
Consequently, during NEEGA-DF cells never come in contact with the separation 
device, and adherent stem cells can be thereby separated and collected without 
adhesion to the wall and cell-cell aggregation. This allows high cell recovery and 
full maintainance of cell viability and differentiation features.  
We have applied NEEGA-DF to a protocol able to purify, distinguish and sort 
human mesenchymal stem cells (hMSCs) from various clinical specimens.64 
65hMSCs are adherent, multipotent stem cells that can be isolated from various 
connective tissues such as bone marrow, fetal membranes, adipose tissue and 
dental pulp. hMSCs are considered promising candidates for clinical applications 
based on cell-therapy approaches. This is also because, other than multipotency, 
they have the very unique characteristic of not provoking an immune response 
when administered into another individual. They are therefore sought as ideal 
source for stem-cell allogenic transplantations. They exhibit differing lineage-
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65
 B.Roda, G. Lanzoni, F. Alviano; A. Zattoni, R. Costa, A. Di Carlo, C. Marchionni, M. Franchina, et al. (2009). A 
Novel Stem Cell Tag-Less Sorting Method. Stem Cell Reviews and Reports, 5, 420–427 
47 
 
commitment yields and differing expression levels of pluripotency markers, very 
likely because of the presence of dissimilar progenitor cells. This makes difficult to 
apply techniques based on immunotagging for hMSC sorting. For these reasons, 
they have been ideal case samples for the application of the NEEGA-DF protocol. 
The protocol can be applied to separating hMSCs from potential phenotypically 
different contaminants when cells are isolated from clinical specimens, thus 
allowing one to reduce the number of cell culture passages for MSC selection; to 
distinguish MSCs derived from different sources, and finally to sort stem cells from 
an MSC population isolated from a single source, obtaining the highest 
differentiation yield. The protocol then represents a new tool for tag-less stem cell 
purification and sorting of stem cells which can be easily integrated in conventional 
cell-sorting platforms to reduce time and improve fully functional stem cell yield. 
 
Fractionation 
 
System setup 
The fractionation device was a ribbon-like capillary channel comprised of two 
polyvinylchloride walls sandwiching a thin foil of polyethylene terephthalate from 
which the channel volume had been removed. Channel dimensions were 2.0 cm in 
breadth, 0.025 cm in thickness and 30 cm in length. The ensemble was 
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sandwiched together using proper clamping systems, which may if necessary be 
removable clamping systems such as nuts, bolts or rivets (Figure 2.3a). 
The fractionation device should be prepared with the following instrumental set-up, 
as shown in Figure 2.3b: 
-a peristaltic pump, used to impart the mobile phase into the system, was 
connected at the channel inlet by means of a T-valve; 
- the T-valve was connected to a PEEK inlet tube (L= 7 cm, i.d. = 0.750 mm, o.d. = 
1/16”) screwed at the beginning of the channel wall used to allow flow and sample 
injection. 
- at the fractionation device outlet, a UV/Vis detection system was connected to 
monitor the elution process, recording a signal at 600 nm; 
- a fraction collector was connected downstream of the detector outlet to collect 
eluted cells.  
-The overall system was placed in a laminar-flow hood to assess sterile conditions. 
The system was placed in a horizontal position to make the gravitational field act 
perpendicularly to the carrier liquid flow. 
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Figure 2.3a: Exploded view of the prototyped fractionation device 
 
 
 
Figure 2.3b: Scheme of the prototyped fractionation system 
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Protocol 
A representative protocol is schematized in Figure 2.4. It consists of: 
1. Sterilization of the fractionation system and conditioning to be performed at the 
beginning of each working day: 
-fill the fractionation system with the sterilization solution for 1 hour at 1 ml/min; 
-fill the fractionation system with sterile water for 1 hour at 2 ml/min to thoroughly 
wash the system and eliminate active chlorine traces; 
- fill the fractionation system with sterile mobile phase for 30 minutes at 0.5 ml/min 
before sample injection for channel wall conditioning.   
- The 100-µL HPLC syringe to be used for sample loading is itself sterilized with 
the same hypochlorite solution and then washed twice with sterile water and finally 
with sterile mobile phase. 
2. Preparation of a cell sample: cells are counted and resuspended in the mobile 
phase at a concentration of 3x105 cells/ml. Cells need to be properly maintained in 
suspension to avoid cell aggregation. 
3. Injection of cell sample: a volume of 50 μL of the suspension are injected into 
the channel PEEK inlet tube (L= 7 cm, i.d. = 0.750 mm, o.d. = 1/16”) by means of 
an HPLC syringe. The flow is stopped for some seconds to allow all samples to 
enter the channel; then by means of a T-valve the inlet port is closed.   
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4. Elution of cell sample: after injection, the flow is immediately restarted and set at 
0.46 ml/min. After a relatively short period of time from injection (about 30 
minutes), cell elution was complete.  
5. Cell fraction collection. When necessary, eluted cells are collected at the 
fractionation device outlet as selected fractions.  
6. Isolation of fractionated cells, and possibly further characterization/selection 
and/or in vitro expansion thereof. 
 
 
Figure 2.4: Stem cell fractionation protocol 
 
Moving from the NEEGA-DF technique, the whole technology was developed and 
transformed in a brand new instrumentation with the aim of bring the new tool on 
the market of regenerative medicine.  
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The property of the invention : Stem Sel srl 
Stem Sel® Srl is a spinoff company participated by AlmaCube Srl, the incubator of 
the University of Bologna and Unindustria. The business project is also supported 
by Regional actions to support the creation, development and improvement of the 
business idea. It is based on the development, the engineering, the manufacturing, 
and the commercialization of the instrument Celector® (and related disposables), 
currently at prototype phase. This product is based on an innovative and patented 
technology for the separation and selection of human stem cells from adult tissues, 
such as “discarded” tissue (e.g. placenta, umbilical cord blood or lipoaspirate). The 
aim is the characterization, the quality control and the future use for cell therapy 
applications in Regenerative Medicine. 
Stem Sel® thanks to this team made by strong multidisciplinary characters and 
highly qualified scientists, has the perfect combination of professional profiles to 
guarantee the prospect of success. 
The Product: Celector® 
Celector® is the novel technology for cell separation that has the key advantage to 
sort both cells from rough tissues rough and ex vivo cultured cells without any sort 
of manipulation. This allows cells maintaining their native proprieties, and stem 
cells their potential. No immuno-tagging is required for cell sorting, and the 
absence of any type of cell manipulation allows passing regulatory restrictions. 
Moreover, our tag-less technology allows for selection/sorting of those stem cell 
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types for which there are not, as yet, efficient  technologies on the market. In fact, 
fluorescence/magnetic-activated cell sorting (FACS/MACS) technologies do 
manipulate cells using immunomarkers, which otherwise might be not available or 
be poorly specific to efficiently select highly potent stem cells such as the 
mesenchymal stem cells  (MSCs). Nevertheless, MSCs are among most-promising 
adult stem cells for clinical applications. Novelty and unique features of Celector® 
then make it a potential “leader tool” among technologies and devices for cell 
therapies. 
Stem cells are distributed in all tissues. They can be then sorted from such 
sources. However, their localization in each source tissue is not well defined, and 
they cannot be identified in a specific district isolated from all different cells, which 
are more differentiated and originated from the stem cells. Moreover, the lack of 
homogeneity in pluri/multipotent SCs severely hinders a definition and 
standardization for successful stem cell-based therapies. Finally, cell-type-specific 
markers such as cell surface proteins are limited known, and they often recognize 
multiple members of a SC lineage. Stem cell recovery and functionality are also 
affected by immunolabeling. Methods that are less dependent on the identification 
of particular markers for SC subpopulations, and which exploit differences in 
biophysical cell characteristics, are therefore promising when it comes to identify 
and sort homogeneous SC subpopulations MSCs are am0ng most-promising adult 
stem cells for cell therapy applications.  
They are adherent, multipotent SCs that are present in quite a few “discarded” 
tissues. However, MSCs express a so-rich and diversified panel of surface 
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antigens that limits the possibility to efficiently “distinguish” MSCs on a immuno-
phenotypical basis. To obtain homogeneous stem cells, particularly MSCs, which 
are properly characterized, safely usable, and in sufficient number, proper methods 
of isolation/enrichment/sorting are then required. 
Celector® does operate sorting with no immuno-tagging. Its proprietary separation 
process exploits differences in the intrinsic characteristics  of the cells, which 
include size, density and surface properties. Cell sorting occurs in a biocompatible 
fluid (PBS-phosphate buffer saline, physiological solutions, culture media) through 
the sterile fluidic device that can be disposed once used. The separation process 
avoid cell contact, and consequent adhesion on the separation device, and cell-cell 
aggregation by using in-flow injection of cells and a proprietary combination of 
different flow stream rates able to keep cells away from the channel walls, and be 
swept down the separation device at different velocities. This can make different 
cells be collected at different times in sundry containers.  
The flow rate values typically applied guarantee low shear stress on cells. After 
fractionation is completed, native physical features then are fully restored. This 
allows high cell recovery and full maintainance of cell viability and differentiation 
features. 
 
The Celector® is composed by this subsystems listed below and described 
following.  
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Figure 2.5: overview of Celector® 
 
A. INJECTION SYSTEM 
1. Autosampler 
2. Pump (PC controlled) and valves  
3. Biocompatible fluids for cells separation  
B. FRACTIONATION DEVICE 
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4. Capillaries for fluidic transport of cells to the separation device and to the 
detection system  
5. Proprietary cell fractionation device using the proprietary process for cell 
separation (single or multi-channel option) 
C. DETECTION SYSTEM 
6 Optical detection (PC controlled): it counts, record and recognizes all kind of 
fractionated cells 
D. FRACTION COLLECTOR 
7. Fractionated cell collector (PC controlled) 
 
 
Hardware and functions 
 
Subsystems of Celector 
 
The instrument is composed of several subsystems dedicated to the carrying out of 
different operations that characterize the operational mode. 
In Figure 2.1 are represented the different subsystems of the instrument, described 
in the following paragraphs.  
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Figure 2.6: subsystems composing Celector®  
 
 
Injection system / Autosampler 
The injection system allows inserting the cell sample into the fractionation system, 
sucking the sample from the tube and injecting it automatically into the fractionation 
system, according to previously defined protocols and setting up defined by the 
operator. The injection procedure is performed by a dedicated peristaltic pump and 
a series of valves, which controlled via software drive the sample from the 
Eppendorf to the fractionator by silicon tubes. 
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Figure 1.7Injection system 
Fractionation system 
 
The fractionation system is the heart of the technology, which perform the 
separation of cells as discussed before. It is part of consumable kits because of 
giving the possibility to replace the fractionator when desired to avoid 
contamination sample-to-sample or run-to-run. It consists of a multilayer 
disposable device of plastic material where both the separation flow and the cell 
suspension are injected through an automated system of capillary tubes. Figure 
2.8 represents the fractionation channel consisting in 5 layers of PMMA, laser 
cutted to create the fluidic circuit. The layers are sealed to each other by means of 
a clamping system. 
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Figure 2.8 layers composing the channel in exploded view (above) and top view 
(bottom) 
Clamping system  
The clamping system is essential to seal the fractionation system ensuring the 
hydraulic seal of the transport fluid and the cell sample. In figure 2.9 it is 
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represented the system employed in the prototype version, and consists in two 20 
mm thick aluminum plates held together by bolts tightened at a specific force. 
 
Figure 2.9 clamping system consisting in Aluminum plates. The most reliable 
clamping system at now.  
Pumping System 
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Figure 2.10 pumping system: double syringe pump and stepper motor peristaltic 
pumps 
The pumping system (fig. 2.10) manages all the flows, is PC controlled and set up 
to create the appropriate flow profile inside the separation device. Pumps are 
connected each other and to the fractionation system by the piping system. The 
syringe pump was implemented for the generation of the central flow, which is 
responsible of the sample separation, in reason of the continuous and not-pulsed 
flow able to produce. Conversely the peristaltic pumps show a pulsed flow, but 
were selected for the lateral flow dispensing and for the injection procedure 
because the irregular flow is not important for their functions. The first one rotate so 
slowly (at a flow rate in the order of 1/10 respect to the central flow) that the 
frequency of pulsation is not appreciable. The second one operates out of the 
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separation chamber except during the in flow injection for small defined interval of 
time, but it’s convenient using a stepper motor pump in reason of the accuracy of 
the volume processed, leading to a repeatable and standard volumes handling.  
Detection System 
 
Figure 2.11 Detection system 
The optical detection system (fig. 2.11) is used for the on-line counting of the 
processed cells during the separation. A dedicated software was developed by the 
internal team in order to control the separation process, returning the cell amount 
for each fractions, characterize the morphology of different populations, manage 
the collector system during the fraction collection.  
The main hardware components of this system are a ultrabright LED illuminator, a 
semi-plan objective 4X magnification and a BlueFox MatrixVision camera. 
Collection system 
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The collection system (Fig. 2.12), allows the automatic collection of the cell 
selected fractions exit from the fractionation system in Falcon tubes both of 15 ml 
and 50 ml volumes, according to user-selected collection times and preferred 
tubes. An holed PMMA circle rotates thanks to a stepper motor, shifting from a 
tubes to the other. 
 
Figure 2.12 collection system 
Graphic User interface (GUI) 
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Figure 2.13 GUI 
The Celector® prototype is controlled via a graphical user interface illustrated in 
Figure 2.13 can be installed on every PC. The graphical interface make the 
instrument easy-to-use also by not specialized personnel, thanks to the possibility 
for  users to interact with electronic devices through graphical icons and visual 
indicators. 
 
External case 
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Figure 2.14 Mechanical support 
The mechanical structure with frame function of the prototype is shown in Figure 
2.14. The size of the current prototype is about 850 x 400 x 400 mm. Despite the 
inappropriate dimension for a Medical Device or a Biotech Lab Tool, the prototype 
fits in the laminar hood so that cells can be prepared and separated in sterile 
conditions, feature that allows also long term biotech characterization of the 
separation product without any contamination. The development of the external 
case will permit maybe also to move the instrument from a hood to another or to 
process the separation out of the hood maintaining the sterility inside the case. 
Piping system 
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Figure 2.15: hydraulic circuit 
The hydraulic system is thought to be disposable and replaceable when needed. 
Moreover was developed in compliance with the requirements of Medical Device 
class IIb, so materials and methods were developed and tested in this point of 
view. These considerations lead to a circuit that has not to be touched from 
components of the machine, so it is composed by silicone tubes, connected 
through adaptors, valves and connections MD compliant and assembled in clean 
room (at the prototype stage is only sterilized once assembled). The flow in silicone 
tubes is managed by electroclamp valves which open and close tubes clamping 
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them by a solenoid, so these valves act on the external surface of the tubes never 
enter in contact with. 
 
 
Operational mode: the main 
phases 
 
1. Purge 
Once switch on the instrument start the purging phase in order to eliminate air 
contained in piping and in the fractionator system. Subsequently, the tubes are 
filled with sterile solution (demineralized water or PBS). 
2. Sterilization 
During this phase are eluted in the fractionation device in succession sodium 
hypochlorite and double-distilled sterile water. This is necessary to further sterilize 
the device in the case has already been used and washed. It can be omitted in 
case the new consumable has just been inserted and then a phase of sterilization 
is not required. 
3. Conditioning 
During this phase in the fractionating device are eluted in succession the coating 
solution (PBS and 1% BSA) , in order to saturate plastic free sites that would bond 
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to cell surface holding it on the accumulation wall, and the the mobile phase 
solution (usually PBS and  0.1% BSA) to wet very well the channel for optimal 
separation conditions. 
4. Running 
Represents the actual procedure of separation in which the cell suspension is 
injectied to be separated and then collected for next proposal. Eluted cell fractions 
are automatically collected in the appropriate tubes. 
5. Cleaning 
This phase provides for the elution in succession of sodium hypochlorite and sterile 
distilled water inside the fractionation device in order to clean the hydraulic circuit 
from cell residues and after rinsing the circuit avoiding the deposition of salts. 
 
 
 
 
Software interface Operations  
During the instrumental setting and parameters definition, to maximize the result of 
the separation and cell count, the researcher will have to consider that:  
 Celector can separate at each run from 50,000 to 1.000.0000 of cells in a 
volume between 50 and 200 l. A run has an average duration of 20 
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minutes and it is possible to operate more consecutive run. Summarizing it 
is possible to separate from 150,000 to 3,000,000 cells per hour; 
 The central flow is at the base of the separation, so it has to be choose 
evaluating the dimension and shape of cells. Default flow rate is set at 1 
ml/min   
 
1) Presence of the consumables and separation liquids 
 
 
Figures 2.16: Ready Status Channel 
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Once switch on the Celector and played the software, the latter this will control the 
fractionation channel presence inside the machine and will give an output to the 
user. 
 
 If the fractionation channel is already present, the user can proceed to the 
next operation. The channel can be used for a limited number of runs. When 
the limit is exceeded the channel will have to be replaced because it can no 
longer perform good quality separations. 
 If the fractionation channel is not present the software will ask the user to 
place the consumable before continue 
Once the channel is inserted the user must specify whether it is a single channel or 
double channel to set up the fluidic regime. 
 
Tubes 
 
Tubes are parts of the disposable and have to be set up in the instrument. A 
colored tubing set help the user in the placement. It was programmed to create a 
video reproducing the set up of piping. 
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Containers and liquids for separation 
 
The user must ensure that you have  enough mobile liquids for all the phases, and 
placed in the right order. Stem Sel will supply the liquids for the different 
operational phases: 
- Bidistilled water 
- Coating solution: phosphate buffer saline (PBS) and Bovine Serum 
Albumine 1% 
- Running solution: phosphate buffer saline (PBS) and Bovine Serum 
Albumine 0.1% 
- Cleaning solution: sodium hypoclorite 30% 
All the solution will be sterilized and filtred. It’s under evaluation the typology of the 
liquid containers. 
If liquids are not sufficient for the next phase, the software stops the 
instrumentation. 
 
72 
 
 
Figures 1.17: Not Ready Status 
 
2) Conditioning 
 
The conditioning phase consists in the coating phase and wetting of the 
fractionator.  
The SW allows to decide if conditioning have to be performed in sterile conditions 
or not. In the first option the cleaning solution is pumped through the circuit and 
then rinsed by water.  
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At each stage of operation in the lower part of the screen it will be indicated the 
status of the instrument from a scroll bar, the missing time to start separations and 
pause buttons and abort. 
 
 
Figures 2.18: conditioning 
 
3) Standby 
 
 
In this stage, the machine sets itself in the Standby mode to save liquids (central 
and lateral flow slower)  
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The phase of Standby also active at the end of each run automatically, so as to 
allow the operator to perform different jobs ensuring minimal waste of fluids and 
preserving the collected fractions as set by the operator. 
 
 
 
3b) Preparation of the sample 
 
For the first run you will have to prepare the sample as specified in the manual 
under the following guidelines: 
 the cell suspension should be prepared in eppendorf 1.5 or 2 ml 
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 cell concentration is around / 3x106 ml diluted in PBS (phosphate buffered 
saline) 
 6x105 cells are prepared and bring to volume with PBS at 2 ml 
 
Celector processes about 100 l/run and is able to process automatically, through 
a sequence of run, the totality of the preparation volume. 
 
4) Running 
At the beginning the user decides if the sample is “known” or “unknown”, so if the 
parameters to insert have been previously saved.  
In the first case the parameters allows the counting from the first run, in the second 
case have to be performed a series of run to define the paramenters to enter. 
 
Figures 2.19: Choosing the run not yet analyzed sample 
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The parameters that can changed or evaluated are:  
 The number of these cell populations.  
 The size of the cells. 
 If the cells are adherent or not. 
 The volume to be injected. 
 The central flow. 
 The number of fractions and their populations. 
 The type of test tubes used for the collection (15 or 50 ml). 
 Possible stop flow and its duration. 
 
Figures 2.20: Run Settings 1/3 
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Figures 2.21: Run Settings 2/3 
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Figures 2.22: Run Settings 3/3 
 
During the separation the camera is connected and the user can switch on the 
display from between real time visualization and fractogram like uotput. 
The data relating to the separation and the separation curve are stored and 
available to the operator for later elaboration. 
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Figures 2.23: Running 
 
5b) Fraction collection 
 
Each fraction will be collected in a test tube, from 15 to 50 ml depending on the 
option selected by the user. 
 
5) Washing 
 
Two washing procedures are available, in reason of the proprieties of the 
processed samples: light and heavy cleaning.  
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Chapter 3 
Development of Celector® 
 
With the aim of bringing to the market a technology which marries the needs of the future 
users, and the industrialization requisites, I paid particular attention to the “heart” of the 
technology, which is the fractionation channel. The latter should let cells viable and not 
stressed by the separation process, and most of all, boast a high cell recovery in order, for 
different reasons: 
- reduce the numbers of consecutive runs for fractions accumulation 
- analysis and further characterization of all populations in the sample 
- let the sample untouched, allowing their use in cell therapies 
- process the higher amount of cell both in reason of high cell number required for 
therapies and of the separation of representative parts of the whole sample. 
The new channel configuration implements a sort of fluidic guide in order to obtain a high 
cell recovery and avoid the contact of cells with the lateral walls of the fractionation 
capillary channel. Celector differences from the public-knowledge device used for NEEGA-
DF analysis (Gr-FFF) both in the fractionation channel for the layers assembly and in the 
fluidic system. The Gr-FFF separation channel is a thin layer trapezoidal shaped, where 
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the mobile phase is introduced into one of the two triangular points, flows through the 
whole length of the channel and exits from the opposite triangular point. Inside the 
separative channel, the mobile phase presents a parabolic flow profile, not only in the 
channel thickness where it provides the separation process, but also in channel width 
meaning that the flow velocity at lateral walls is naught. When samples are introduced into 
this separative channel they are subjected to the parabolic flow and they raise the lateral 
walls where they aren’t subjected to any velocities which should carry it to the outlet of 
separative channel, thus a part of injected cells are “entrapped” at the lateral walls, with a 
consequent low cell recovery (no higher than 50-60%).  
The new separative channel design implements two lateral fluidic surfaces with a lower 
flow rate, acting as an external fluidic guide from the separation surface, that allows 
sample not to arrive at lateral walls and remaining always in movements (Figure 2.1). 
External flows are parallel to the separation surface so they are not considered factors 
acting for focus cells (like a flow cytometer) because there is no single-cell focalization. 
Moreover the cell separation profile is better defined and closer to a Gaussian peak profile, 
indicating a more efficient separation process. 
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Figure 3.1 : Previous fractionation channel (left), current and patented fractionation device 
(right) 
 
The Finite Element Method (FEM) analysis of the flow profile inside the separation 
channel, performed with different geometries and simulated with COMSOL Multiphysics 
3.5, allowed to match the optimal geometry with few tests. 
The result of the FEM analysis (Figure 3.2 ) shows the conservation of the lateral fluidic 
guides at different flow rates of the central separation flow for the new geometry. 
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(a) 
 
(b) 
Figure 3.2: FEM output: (a)Total flow profile of the standard channel (b) (a)Total flow 
profile of  the new “parallel” channel at different flow rates of the central main flow. 
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I also optimized the injection system and position, implementing an in-flow injection that 
increases the recovery (adherent cells are not strongly injected against the accumulation 
wall of the channel) and decreases shear forces resulting in a lower stress of cell samples. 
The injection system was crucial in defining the fluidic asset. Traditional Gr-FFF injection 
system is composed by a T-valve and a syringe: the injection of the sample is completely 
performed by hand.  
Biologists believe that the standardization of the separation protocol, in particular during 
the first steps of sample preparation or treatment, is always more requested by cell 
manipulation institutions because it’s decisive for successive phases both for research and 
medical issues. Due to the poor amount of stem cells in a biopsy, the standardization of 
the collection and recovery procedures became essential, in particular during the sample 
characterization phase.  
Citing the Journal of Cell Biology “…the integration of the various processes will be 
required in order to achieve a clinically relevant product through a regulated and controlled 
bioprocess that is reproducible, standardized, automatable (when needed), integrated and 
certified. …”66 
In Figure 3.3 is shown the Gr-FFF instrumental setup with the T valve injection system.  
                                                          
66
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Figure 3.3: NEEGA-DF instrumental setup with two fractionation channels working under 
laminar whood (left), injection system by T valve (right) 
 
This injection system is not reproducible, “lands” the sample against the accumulation wall 
and scatters the suspension in the whole width of the separation volume causing loss of 
cells, presents high dead volumes and introduces air inside the channel compromising the 
separation. Moreover the method operated by biologists for the cell counting Burker 
chamber) introduces further uncertainty about the number of cells injected, or better both 
injected and recovered cells. By the way the error is higher on the injected cells because 
the same volume of the whole solution prepared is analyzed through the Burker chamber 
(usually 0.01 ml), but the volume of the whole solution is different: the volume of the cell 
suspension to be injected and separated is grater (usually 1 ml) than the one to be 
counted for the recovery evaluation (usually 0.1/0.2 ml) 
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The major Burker chamber Producer (Celeromics) asserts: “Errors in the range of 20%-
30% are common in this method due to pipetting errors, statistical errors, chamber volume 
errors, and errors from volume of simple introduced into the chamber. Even though, the 
Burker chamber remains the most widely used cell counting method in the world”.67 68 
To overcome these critical problems, both biotech and engineering aspects were 
considered: the first revising the biotech method in reason to reduce the steps “out of 
control” for the determination of cell concentration in the solution during its preparation; the 
second in reason to think the layout definition starting from the fractionation and the 
injection systems. In particular, part of the injection was included inside the layers of the 
channel, and then controlled by a stepper motor peristaltic pump, reducing systematic 
errors. This strategy dramatically decreases the formation of air bubbles during the 
separation, minimized the dead volumes removing the run-to-run volumes accumulations, 
standardized the injected volumes thanks to the accurate steps of the motor and the 
particular capillaries format and configuration. 
The result of the optimization of the channel shape, the lateral flow rate setting, and the 
injection asset and method are shown in Figures 3.4, 3.5, 3.6, 3.7, 3.8, demonstrating the 
                                                          
67
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absence of contact of cells (both adherent and in suspension cells) with the lateral walls of 
the new fractionation device. In the Figure 3.4 the positions of observation relative to 
following pictures are laid out.  
 
 
 
Figure 3.4: Observation positions on the standard channel (left) and the new channel 
(right) for the evaluation of the best fluidic regime of later guides and the injection protocol. 
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Figure 3.5: Sequence of pictures from the middle(A) to the edge (F) of the new separation 
channel. Dental pulp MSCs (adherent) injection. 
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Figure3.6: Sequence of pictures from the middle (A) to the edge (D) of the new separation 
channel. Blood (in suspension) injection. 
 
 
Figure3.7: Sequence of pictures from the middle (A) to the edge (B) of the standard 
separation channel. Dental pulp MSCs (adherent) injection. 
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Figure 3.8: Sequence of pictures from the middle (A) to the edge (B) of the standard 
separation channel. Blood (in suspension) injection. 
 
Combining the considerations on the channel geometry and the injection system, in order 
to get to an automated product, the composition of the multilayer separation device was 
adjusted including part of the injection between the layers. 
The new device presents five layers stacked together to give the hydraulic circuit. 
Proprieties of layers are described in the Table2.1 and figure out in Figure 2.9 
 
Layer Thickness Material Function 
1 8 mm PMMA  Inlet and outlet of liquids and sample 
2 0.25 mm PMMA Controlled volume of injected sample (0.1ml) 
3 3 mm  PMMA Depletion wall 
   4 0.25 mm     PMMA Lateral walls 
5 3 mm PMMA Accumulation wall 
Table3.1 : Layers composing the fractionation device.  
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Layer 3,4,5 are responsible of the cell separation, Layer 1 and 2 are responsible of the 
injected cell amount standardization and in-flow injection not directly on the accumulation 
wall. 
 
 
 
(a) 
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(b) 
Figure 3.9: Exploded (a) and assembled (b) multilayer channel 
 
The separation methods were defined in a few months, first to merge the results with the 
technological development and second to compare the performances respect to the 
standard technology NEEGA-DF.  
The brilliant ideas and the considerations in depth of the results produced by the research 
team, blossomed to an accurate experimental design that allows the simultaneous 
development of the different parts of the instrumentation with an “overviewed” approach, 
adjusting step by step tools and methods. 
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Figure 3.10: Overlap of separation profiles of mesenchymal stem cells performed with 
standard (___) and new (---) device using the NEEGA-DF method (above),  overlap of 
separation profiles of red blood cells performed with standard (----) and new (___) device 
using the Gr-FFF method (below)   
 
94 
 
One of the first results was the filing of a patent application for the new device and 
separation methods. The patent application in Italy (PA94250IT, “Dispositivo per il 
frazionamento di oggetti e metodi di frazionamento”) was performed in the year 2014, 
while the search report, its response with claims revisions and the filing of the patent PCT 
application (PCT94250) belong to the year 2015.  
 
At the same time was carried on the definition/revision of materials composing the fluidic 
system. The materials were selected throwing in together the medical device IIb 
compliance, the cell manipulation requirements for best separation results, and the 
industrialization requirements as material availability, cost, quantity for lot, order fulfillment, 
manufacturing process feasibility/repeatability, suppliers reliability. From the beginning the 
hydraulic circuit as thought to be used as disposable (replaced also at every run if 
necessary), avoiding any risk of contamination. Accordingly its running is entrusted by 
external tools along the whole hydraulic system, able to manage the flow and the cell 
suspension without any contact with them.  
The best compromise in materials and configuration developed by the research team is 
illustrated in Figure 3.11 and some particulars are shown in Figure 3.13. 
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Figure 3.11: Hydraulic circuit scheme (channel not included) 
 
 
The hydraulic circuit is composed by the components listed below: 
- Silicone tubes 
- Fittings and adaptors for tubing connections 
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- Syringes for pumps 
- Falcon for collection of fractions 
- Check valves  
 
 
Figure3.12: Particulars of the hydraulic circuit 
 
To complete the hydraulic section, it had to be defined how the seal of the stacked layers 
constituting the channel would be guaranteed. This topic represented the “technological 
challenge” of this project, the unsolved trouble which is gripping FFF researchers and 
experts for decades. Our results untie the belief of “unfeasibility”, but have is useful only 
for the start up production with small batches, and needs to be industrialized before the 
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large scale commercialization that will make available Celector® for R&D/medical/clinical 
purposes. 
Conventionally the hydraulic seal of channels for FFF separation is acted by a series of 
bolts distributed along the thin layer perimeter and tightened at a specific force by a torque 
wrench, which depends from a series of parameters (layer material, thickness, width, 
geometry,…). 
The new design of the channel doesn’t allow the use of bolts because the force wouldn’t 
be distributed homogeneously on the surfaces and the deformations originated from the 
tightening force would compromise the parallelism of the layers originating leakages. 
I explored many solutions; some of them were tested with the intention of replace bolds 
passing to a “light” device that replace the “heavy” mechanical arrangements, the latter 
inappropriate for cell manipulation and for disposable usage. 
The technological challenge was very hard. 
Some examples of bolding and press-like sealing systems are reported in Figure 
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Figure3.13: from the left: bolds, Aluminum plates to uniform the force on the whole channel 
surface, engineered press-like solution, Aluminum plates which allow the detection. 
 
 
Others manufacturing solutions failed due to the numbers of the layers: too many or too 
few. 
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Figure 3.14 : Laser welding tests with different  materials. 4 of 5 welded layers 
 
 
Figure 3.15: Milling machining tests. 1 of 2 layers treated: on the left the assembled 2 layer 
channel, on the right the picture under microscope of the treated layer. 
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In the Figures above are exampled two representative cases of welding technologies and 
processes tested to replace the external mechanical tightening system in reason to obtain 
a self sustained channel easy-to-use for future costumers. 
At now there’s an only procedure that guarantee the hydraulic seal of the channel in 
working conditions, even if the solution isn’t ndustriaslizable on large scale.  Preliminary 
tests have been performed to optimize the production process for the first lots intended for 
beta testing phase.  Meanwhile new tests on different techniques more appropriate to 
large scale production, are scheduled and will be worked out during the beta testing, 
receiving advantageously the first feedback of testers. 
The working solution implements a Double-sided adhesive tape, which replace the thin 
layers of the separative channel.  
Layers 2 and 4 are so replaced by a tape meting together upper and lower layers without 
significant loss of the parallelism also under stressed conditions. Two materials replacing 
the thin layers were tested, with good results in the polyester tape assembled device. 
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Figure 3.16: Prototypes of self-sustained channel. The thin PMMA layers are replaced by 
(1) Acrylic foam and (2) polyester biadhesive tape layers of the same thickness respect to 
PMMA layers. 
 
The device assembled with polyester tape overcomes to all working phases of Celector® 
without any support, The separation proprieties were studied both with standard particles 
with a density similar to the cell one, and with MSC cells in order to adjust the 
manufacturing and processes of production phases, achieving the firsts lots of self-
sustained channels to place on the market.  
Two revisions were tested improving both the separation features and the behavior in the 
different phases of working. In particular, began the study about the interaction with the 
cleaning solution and the toxicity tests in order to validate the biocompatibility.  
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Figure 3.17: Sedimentation of salts on the edges of biadhesive layers 
 
We noticed that the adhesive tape is different after some separation runs. The edge of the 
tape is altered and it seems that salts into the separation buffer and cleaning buffer 
sediments on the edge of the tape. This leads to holes obstructing and prevention of the 
liquids flow. 
A first series of improvements about the manufacturing process was performed in reason 
of these considerations highlighted by the supplier and discussed fort better results (Figure 
3.18): 
- Plastic layers get electrostatically charged by removing the protective cover film 
and dust particles or plastic residues of laser cutting accumulated on the surface.  
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- The screw connections already contain a lot of residues produced during the 
previous threading process 
- The PMMA plates are deformed during the laser cutting procedure that melts the 
edges through the heat released 
 
 
 
Figure: 3.18 Problems observed during the assembling, caused by previous 
manufacturing. 
 
So we considered to add two steps before the assembling:  
1. Edge smoothening 
2. Ultrasonic cleaning in demineralized water 
 
Four channels were assembled implementing the discussed procedures. 
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Two of them were designated to the separation method validation; one each was given 
over to engineers and to biologists. Main goals for each concern: 
1. Stability of the fluidic system, material stress resistance, software adjustments, 
hardware components evaluation/replacement/placement, repeatability of the 
method, shelf life estimation, dead volumes tests, recovery and counting software 
tests, draft of the certification agreements and risk analysis annexes. 
2. Sterility subsistence, easy-to-use evaluation, interaction with cells both “in flow”/“in 
flask” conditions, interaction with biotech instrumentation equipment and ease of 
access to labs (e.g. no ground in sockets of laminar hoods and of the most of labs 
meant get shock every time a conductive material was touched, obviously this 
hampered the use of Celector till the problem was identified and solved), optimizing 
the timing of every phase,  cell recovery, 
 
The fluidic characterization of Celector® was performed studying different aspects with 
different separation protocols. For example, we set a sequence of experiments in order to 
determine the repeatability of separation with the new fluidic circuit using PMMA 
standards. PMMA microspheres are an optimal alternative to cells, because of their similar 
density and dimensions (0.015 mm) respect to Mesenchymal stem cells. 
This characterization is performed in order to confirm that the separation proprieties are 
suitable for the separation of cells and the separation is repeatable.  
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In Figure 3.19 are shown the overlap of separations performed in different days. The 
retention times of aggregated and single particles are not different in every run, 
demonstrating the stability of the fluidic system. 
 
 
 
Figure 3.19: Overlap of separation profiles of PMMA particles in different days 
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Biological validation of the sealing solution was performed in parallel.  
Toxicity tests can be chosen on different basis. We need to do specific and punctual tests, 
with a good reliability and short timing. We chose the Direct Contact Method: 
1. A near confluent layer of fibroblasts are prepared in a culture plate (24 wells with 
HOS cells plated at 1.500 cells/well) 
2. Old cell culture media is removed 
3. Fresh media is added (IMDM + PS 1% + FBS 10%) 
4. Material being tested is placed onto the cultures, which are incubated for 24 hours 
at 37 degrees Celsius (biadhesive 2mmx1cm) 
 
The plates, prepared in duplicate to avoid contamination or confluence problems, are 
made by these specifications: 
- Positive Control (C+ cells in culture media) 
- Negative Control (C- cells + 30% bleach in H20)  we assume that was the 
contamination with bleach the cause of cell death in the previous experiment 
- Sample + biadhesive washed with sterile H2O  
- Sample + biadhesive washed with 30% bleach and sterile H2O  
 
After 24 hours at 37 degree Celsius, cells are as shown in fig. 3.20: the biadhesive shows 
no toxicity for cells, both biadhesive washed with only sterile water and washed with 
bleach. The material is floating and not adherent on the wells. Positive control (cells in 
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culture media) is suffering more than the sample with the material. Negative control is 
made by cells in culture media with 30% bleach and they are dead (as we want). 
 
 Positive control     Negative control          Washing liquid 
 
Figure 3.20: Toxicity test results 
 
Results demonstrate: 
- The biadhesive is biocompatible. 
- The biadhesive releases some molecules/substances promote cellular adhesion on 
plates 
 
The detection system replacing the usual absorbance signal consists in the counting of 
cells during the separation.  
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The approach was to identify the concentration distribution function  of the injected cells, 
along the width of the channel, so as to obtain the multiplicative factor that allows to 
extrapolate the total number of cells fractionated for each fractionation. 
The procedure to derive the distribution function was: 
- Consider the width of the channel consisting of two symmetrical halves A and B 
(Figure 3.21) in which it is assumed that the analytes are arranged in the same way 
- Divide one half (A) in several regions of observation called windows. (Figure 3.21). 
The windows are near to the collection point f to ensure that the separation process 
is terminated, and then the number of cells counted corresponds to the number of 
collected cells or present in the collection tube 
 
Figure 3.21: Partition of the channel in observation windows 
- Take a sequence of pictures during the cell separation positioning the optical 
system in correspondence of the window.  
- Move to the next window till the edge of the channel 
- Once determined the distribution of concentration along the width of the channel 
which considers the percentage of cells crossing every windows, the rough data 
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(number of cell counted) will be multiplied for the parameter find out from that 
function 
 
The elaboration of the counting software is based on the image analysis normalized on 
the velocity of cells crossing the window in reason to count every cell only once.  
The image analysis operates as described: 
 
1. loading the image (previously scaled) 
2. subtraction between the image and the background image (without cells) 
3. erosion + dilation of the image obtained so to eliminate the edges  
4. from color image to grayscale transformation 
5. application of the threshold effect 
6. Cell contours detection and perimeter calculation 
7. Discard of inadequate particles having too high or too low perimeter (bubbles, 
impurities,…) thanks to a size operating filter  
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Figure 3.22: Borders detection during the separation 
 
The software needs the diameter of injected cells for the calculation of the perimeter, so 
distinguish cells from the background, and to set the dimensional cut off.  
Several versions of the counting algorithm were experimented but no one fitted the actual 
amount of processed cells, or better the parameter find out from the statistical analysis 
presented a too high error to be considered reliable. 
The best result obtained, where the cell number was closer to the actual amount of 
processed cells gave the concentration profile as in Figure 3.23, and relative separation 
profiles (observed in the window 1) as in Figure 3.24. 
This series of experiments was performed using Dental Pulp Mesenchymal Stem Cells 
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Figure 3.23: Distribution concentration profile obtained from the counted cells in every 
window 
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Figure 3.24: Separation profiles of processed cells registered in window 1 
 
The average cell number counted by the software in every window is below reported in 
Table 3.2 
Window Avarage cell number 
4 s 0 
3,5 s 1900 
3 s 11720 
2,5 s 14785 
2 s 19869 
1,5 s 21826 
1 s 24921 
1 57838 
1,5 46026 
2 43498 
2,5 39404 
3 36584 
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3,5 16098 
4 0 
  
Total cells 359129 
 
Table 3.2: rough data obtained from the counting software in every window exploring 
the whole width of the channel: windows from 1 to 4 are in the right half, windows from 
1s to 4s are in the left half. 
 
The trend of the distribution profile is not parabolic as predicted by FEM studies. The 
profile obtained is not symmetrical, probably due to the closing system (aluminum plates) 
which deforms the layers of the channel because of the punctual applied force creating an 
irregularity of distribution on the surface. This results in asymmetrical asset of the 
fractionation device. 
Then considering as reference value the average number of cells counted in the window 1, 
the variation of cells counted with respect to the window 1 for the other windows was 
calculated normalizing the counted cells on the cell velocity and the number of frame 
registered by the optical system. 
The sum of the variations for every window returns the value of the multiplier parameter. In 
this case he result of the total count is equal to 359.129, respect to the number of 
processed cells equal to 300.000. The counting software overestimates the count of about 
30%. 
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In the end we decided to adjust the channel geometry in the first instance so to detect the 
totality of processed cells Figure 3.24.  
 
 
 
 
Figure 3.24: Channel configuration for the detection of all the particles processed 
 
This is a software simplification and, at the same time, a hardware complication, due to the 
grater linear velocity reached by cells entering the shrinkage. The hardware have to be 
replaced by with more performing tools, to allow the visualization of the observation 
windows through a brighter illuminator, the catching of defined pictures through shorter 
exposure time meaning a faster camera, which however needs to faster communicate with 
the microcontroller avoiding its overloading. 
Actually this study has the only goal of settle the detection system, because the channel 
itself has a width range going from 40 mm to 2 mm, so the position of the detection system 
determines the percentage of the channel observes for the count. 
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In reason of these considerations will be planned experiments to define the right 
configuration. 
 
 
The use of Celector® technology was made available for beta testing phase, during which 
will be used by cell processing labs, thanks to the development of the management 
software.  
The software features: 
-  the interaction with the user via a graphical user interface (GUI) where the actions 
are performed through direct manipulation of the graphical elements. 
-  the full automation of the processes, controlled by personal computer that 
communicates with the Arduino implemented on board of the technology and with 
the PCB of the syringe pumps by a serial port RS232. 
 
 
The automation software was developed outlining flowcharts describing every working 
phase: conditioning, running, washing and standby phases. With the possibility to choose 
“single” or “double” channel fractionator device. 
An example of flowchart for the Running phase in Figure 3.25 
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Figure 3.25: Flowchart of the Running phase, useful to drive the writing down of the 
Automation software and for the debugging.  
 
The interface allows the not specialized personnel in using the Celector® through 
graphical icons and visual indicators. The outfit of the GUI realized is shown in Figure 
3.26. 
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Figure 3.26: graphical user interface of Celetor® 
 
Within this window it’s possible to set: 
1. the different fractions to collect (from a minimum of 1 to a maximum of 6). It’s possible to 
set a no-collection time between two fractions.  
2. the number of consecutive run  
3. the type of cells and their parameters (default values are implemented and refer to 
tested samples) 
4. the total time of the run so to return in the stand-by modes avoiding liquids wasting. 
5. the “stop flow” analysis and its duration 
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6. the volume injected for every run 
7. the separation flow rate actuated by syringe pumps 
8. 9. saving favorites parameters and the desired folder 
10. apply for the setting of the instrument 
 
During the run it is possible to play both the movie of cells crossing the camera or the 
separation profile given by the counting software. 
At the end of each run the data are saved to files in the folder and the graph is saved in 
two different formats (PNG and PDF) as well as the cellsdata file containing the individual 
count for each frame and the file out with the total count of cells. 
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Conclusions 
I consider my PhD period as a real opportunity to bring my knowledge, my 
proficiency, my creativity, within reach to whoever might be useful. All the team 
played a central role reaching a fully function instrumentation to bring in 
manipulation labs. Many aspects are uder revision and development optimizing the 
whole system in the hope to reduce the testing phase, first implementi the right 
solutions paying attention to future customers needs. 
The aim of the PhD is to act as a bridge between the academic world and the 
industrial one and the goal was reached. 
The instrument developed during these years was tested also with biological 
samples, not reported in this thesis because not published yet. During the next 
years the beta tesing phase will produce final results to implement this work in a 
complete manual of a research device. 
The excellence shaped by the University of Bologna stands out, once again, with 
an innovative product, thanks to the support of ALMACUBE which get by and 
coached the team, aiming to the formation and to the maximum efficiency oriented 
to business return and development.  
The project reached very high levels and there is the need of an instrumentation  
so innovative  
Compared to the market benchmark, you can then highlight the following 
innovative aspects: 
1. EXCLUSIVE APPLICATION: the only instrument on the market able to select 
multipotent cells (e.g. Mesenchymal ) without the use of markers. 
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2. NO HANDLING/MANIPULATION: cells not only are selected without 
immunolabeling, but also without any contact with the separating device: the cells 
are simply suspended / diluted in a physiological buffer solution (e.g. phosphate 
buffer, PBS). 
3. EASY-TO-USE AND TIME OF USE: before being introduced in Celector® the 
desired number of cells, is only requested a centrifugation. It is not necessary the 
marking process, which usually takes at least 2 hours. The injection of the cells 
occurs through an automatic injection system easy-to-use. 
The first prototy are the perfect way to explore the market and deep study the 
development strategy. 
 
 
 
 
